

## Medications Requiring Prior Authorization

Effective: December 1, 2023

The following list outlines medications that require review by the clinical pharmacist, and in some cases, a FirstCarolinaCare medical director. If your doctor asks for coverage of a drug that requires prior authorization, he or she must provide documentation to meet criteria for that particular medication. Providers must request prior authorization from FirstCarolinaCare for drugs on this list.

This list is subject to change.

To request a written copy of the coverage criteria, please contact FirstCarolinaCare Member Services at (855) 291-9336 for TTY users, 711, 8 a.m. to 8 p.m., local time, seven days a week. From April 1 – September 30 voicemail will be used on weekends and holidays.

FirstCarolinaCare Insurance Company is a health plan with a Medicare contract. Enrollment in FirstCarolinaCare depends on contract renewal.

This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments and restrictions may apply. Benefits and copayments/co-insurance may change on January 1 of each year.

This information is available for free in other languages. Please contact our Member Services number at (855) 291-9336 for additional information. (TTY users should call 711.) Hours are from 8 a.m. – 8 p.m., local time, seven days a week. From April 1 – September 30, voicemail will be used on weekends and holidays.

Esta información está disponible sin cargo en otros idiomas. Para obtener información adicional, llame al Departamento de Servicios para los Miembros al (855) 291-9336. (Los usuarios de TTY deben llamar al 711). Nuestro horario de atención es de 8:00 a.m. a 8:00 p.m., horario local, los 7 días de la semana. Desde el 1.º de abril hasta el 30 de septiembre, puede dejar un mensaje de voz los fines de semana y feriados.

## AAT DEFICIENCY

---

### Products Affected

- Aralast Np INJ 1000MG, 500MG
- Glassia
- Prolastin-c
- Zemaira

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Doc of high-risk phenotype (e.g. PIZZ, PIZ(Null), PI(Null)(Null), plasma AAT level below 11 Micromol/L (corresponding to 80mg/DL) FEV1 greater than or equal to 35% and less than 80% of predicted ability to comply with protocol for administration
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. Coverage is limited to a dosage of 60mg/kg weekly.

# ABELCET

---

## Products Affected

- Abelcet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Invasive Aspergillosis, Blastomycosis, Candidiasis, Cryptococcosis, Leishmaniasis, Systemic Mycosis: in patients refractory to or intolerant of conventional Amphotericin B therapy, Pulmonary aspergillosis: chronic (cavitary or necrotizing) salvage therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	Subject to BvD decision.

# ACTEMRA

## Products Affected

- Actemra
- Actemra Actpen

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	All Indications (initial, reauth): Patient is not receiving Actemra in combination with a biologic DMARD (e.g. Enbrel (etanercept) (etanercept), Humira (adalimumab) (adalimumab), Cimzia (certolizumab)).
<b>Required Medical Information</b>	Polyarticular Juvenile Idiopathic Arthritis (PJIA): Diagnosis of active PJIA and one of the following: A) Trial/failure, contraindication, or intolerance to TWO of the following: Enbrel (etanercept), Humira (adalimumab), Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy if within the past 120 days. Rheumatoid Arthritis (RA): Diagnosis of moderately to severely active RA and one of the following: A) Trial and failure, contraindication, or intolerance to TWO of the following: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib) (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy if within the past 120 days. Systemic Juvenile Idiopathic Arthritis (SJIA): Diagnosis of active SJIA and a trial/failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally indicated doses: a minimum duration of a 1-month trial of a nonsteroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen), OR a minimum duration of a 2-week trial of a systemic glucocorticoid (e.g., prednisone), OR a minimum duration of a 3-month trial and failure of methotrexate.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy as evidenced by improvement from baseline

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# ADEMPAS

---

## Products Affected

- Adempas

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with severe hepatic disease, creatinine clearance less than 15mL/min or on dialysis, pregnant patients
<b>Required Medical Information</b>	Documentation of previous medications used, results of acute vasoreactivity testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist or Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# AIMOVIG

## Products Affected

- Aimovig

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concomitant use with another Calcitonin Gene-Related Peptide (CGRP) Inhibitor.
<b>Required Medical Information</b>	Episodic Migraines (EM): Diagnosis of EM. Patient has 4 to 14 migraine days per month, but no more than 14 headache days per month. Chronic Migraines (CM): Diagnosis of CM. Medication overuse headache has been considered and potentially offending medication(s) have been discontinued. Patient has greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months. Two of the following (CM): Trial and failure, contraindication, or intolerance (after at least a two month trial) to: amitriptyline or venlafaxine, b) Trial and failure, contraindication, or intolerance (after at least a two month trial) to: divalproex sodium or topiramate, or c) Trial and failure, contraindication, or intolerance (after at least a two month trial) to: one of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol. Medication will not be used in combination with another injectable CGRP inhibitor.
<b>Age Restrictions</b>	EM, CM (initial): 18 years or older
<b>Prescriber Restrictions</b>	Neurologist, Headache Specialist, or Pain Specialist.
<b>Coverage Duration</b>	EM, CM (Initial): 6 months. EM, CM (Reauth): 12 months.
<b>Other Criteria</b>	EM, CM (Reauth): Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity. Use of acute migraine medications (e.g. non-steroidal anti-inflammatory drugs [NSAIDs], triptans) has decreased since the start of CGRP therapy. CM (Reauth): Patient continues to be monitored for medication overuse headache.

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# ALDURAZYME

---

## Products Affected

- Aldurazyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme assay demonstrating deficiency of alpha-l-iduronidase enzyme activity or DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For patients with Hurler and Hurler-Scheie forms of MPS I and for patients with the Scheie form who have moderate-to-severe symptoms

# AMBISOME

---

## Products Affected

- Amphotericin B Liposome

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	Subject to BvD decision.



# AMBRISENTAN

---

## Products Affected

- Ambrisentan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Severe hepatic disease, severe anemia, pregnant patients
<b>Required Medical Information</b>	Documented previous failure of or contraindication to a generic formulary CCB if testing reveals vasoactivity.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist or Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# AMITRIPTYLINE

## Products Affected

- Amitriptyline Hcl TABS 100MG, 150MG, 25MG, 75MG
- Amitriptyline Hydrochloride TABS 100MG, 10MG, 50MG
- Clordiazepoxide/amitriptyline
- Perphenazine/amitriptyline

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Depression: Trial with at least one formulary antidepressant. Chronic Pain: Trial with duloxetine or NSAID. Fibromyalgia: Trial with duloxetine, gabapentin, or pregabalin. IBS: Trial and failure of any two of the following: laxatives, loperamide, or anti-spasmodic agents. Post-herpetic Neuralgia: Trial with gabapentin or pregabalin. Headache: Trial with NSAID
<b>Age Restrictions</b>	PA applies to patients 65 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Provider must submit attestation that benefit outweighs risk of drugs found to be high risk medications for beneficiaries age 65 and older.

# ANTIEMETIC THERAPIES

---

**Products Affected**

- Aponvie
- Aprepitant CAPS
- Cinvanti
- Emend INJ
- Emend SUSR
- Fosaprepitant Dimeglumine

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Chemotherapy-induced nausea and vomiting, due to highly emetogenic chemotherapy, including high-dose cisplatin, prophylaxis or chemotherapy-induced nausea and vomiting, due to moderately emetogenic chemotherapy, prophylaxis, or prevention of postoperative nausea and vomiting
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision.

# APOKYN

---

## Products Affected

- Apomorphine Hydrochloride INJ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concomitantly on a 5HT3 antagonist
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ARANESP

---

## Products Affected

- Aranesp Albumin Free INJ  
100MCG/0.5ML, 100MCG/ML,  
10MCG/0.4ML, 150MCG/0.3ML,  
200MCG/0.4ML, 200MCG/ML,  
25MCG/0.42ML, 25MCG/ML,  
300MCG/0.6ML, 40MCG/0.4ML,  
40MCG/ML, 500MCG/ML,  
60MCG/0.3ML, 60MCG/ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Adequate iron stores shown by Serum Iron and Serum Ferritin within normal range
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision.

# ARCALYST

## Products Affected

- Arcalyst

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Discontinuation with serious infections, concurrent use of TNFS (increased infection risk), Latent TB
<b>Required Medical Information</b>	Cryopyrin-Associated Periodic Syndromes (CAPS) (Initial): Diagnosis of CAPS, including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS). The medication will not be used in combination with another biologic. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Diagnosis of DIRA. Patient weighs at least 10 kg. Patient is currently in remission (e.g., no fever, skin rash, and bone pain/no radiological evidence of active bone lesions/C-reactive protein [CRP] less than 5 mg/L). Recurrent Pericarditis (Initial): Diagnosis of recurrent pericarditis as evidenced by at least 2 episodes that occur a minimum of 4 to 6 weeks apart. Trial and failure, contraindication, or intolerance (TF/C/I) to at least one of the following: nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen), colchicine, or corticosteroids (e.g., prednisone).
<b>Age Restrictions</b>	CAPS, FCAS, MWS: 12 years or older.
<b>Prescriber Restrictions</b>	Rheumatologist, Dermatologist, Immunologist, or Cardiologist
<b>Coverage Duration</b>	Initial: 4 months. 2nd Auth: 6 months. Reauth: 12 months.
<b>Other Criteria</b>	N/A

# BERINERT

---

## Products Affected

- Berinert

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Hereditary Angioedema (HAE) confirmed using Serum Complement Factor 4 (C4), CI Inhibitor (C1NH) Antigenic, and C1NH Functional levels (if available) taken at different times (second test confirms diagnosis)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# BESREMI

## Products Affected

- Besremi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of polycythemia vera as confirmed by all of the following: 1) One of the following: a) Hemoglobin greater than 16.5 g/dL for men or hemoglobin greater than 16.0 g/dL for women, b) Hematocrit greater than 49% for men or hematocrit greater than 48% for women, or c) Increased red cell mass, AND 2) Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic and megakaryocytic proliferation with pleomorphic, mature megakaryocytes, AND 3) One of the following: a) Presence of JAK2 or JAK2 exon 12 mutation or b) Subnormal serum erythropoietin level. Both of the following: 1) Trial and failure, contraindication or intolerance (TF/C/I) to hydroxyurea, AND 2) TF/C/I to one of the following: Interferon alfa (e.g., Intron A) or Pegasys (peginterferon alfa 2a).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist/oncologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve for continuation of prior therapy.



# BOTULINUM A TOXIN

---

## Products Affected

- Botox
- Dysport
- Myobloc
- Xeomin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Use for cosmetic purposes (e.g., wrinkles)
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy from initial treatment. At least 3 months have elapsed since the last treatment.

# CABLIVI

## Products Affected

- Cablivi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Acquired Thrombotic Thrombocytopenic Purpura (aTTP): Diagnosis of aTTP. First dose was/will be administered by a healthcare provider as a bolus intravenous injection. Used in combination with immunosuppressive therapy (e.g. rituximab, glucocorticoids). One of the following: 1) Used in combination with plasma exchange or 2) Both of the following: Patient has completed plasma exchange and less than 59 days have or will have elapsed beyond the last plasma exchange.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A

# CAMZYOS

## Products Affected

- Camzyos

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Initial: Diagnosis of obstructive hypertrophic cardiomyopathy (HCM). Patient has New York Heart Association (NYHA) Class II or III symptoms (e.g., shortness of breath, chest pain). Patient has a left ventricular ejection fraction of greater than or equal to 55%. Patient has valsalva left ventricular outflow tract (LVOT) peak gradient greater than or equal to 50 mmHg at rest or with provocation. Trial and failure, contraindication, or intolerance to both of the following at a maximally tolerated dose: a) non-vasodilating beta blocker (e.g., bisoprolol, propranolol) and b) calcium channel blocker (e.g., verapamil, diltiazem).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Initial, Reauth: Prescribed by or in consultation with a cardiologist.
<b>Coverage Duration</b>	Initial: 16 weeks, Reauth: 12 months
<b>Other Criteria</b>	Reauthorization: Documentation of positive clinical response to therapy (e.g., improved symptom relief). Patient has a left ventricular ejection fraction of greater than or equal to 50%.

# CARBAGLU

## Products Affected

- Carglumic Acid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency: diagnosis of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase confirmed by enzyme analysis or DNA mutation analysis. Patients who do not have enzyme analysis or DNA mutation analysis results can be approved for a one month trial pending results. Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA): diagnosis of hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CAYSTON

---

## Products Affected

- Cayston

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Cystic Fibrosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist or Infectious Disease Specialist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CERDELGA

---

## Products Affected

- Cerdelga

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	CYP2D6 phenotype determination testing. Diagnosis of non neuropathic (Type 1) Gauchers Disease
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Physician who specializes in the treatment of Gauchers Disease
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CEREZYME

---

## Products Affected

- Cerezyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme Assay demonstrating deficiency of beta-glucocerebrosidase enzyme activity. For long-term ERT in pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher Disease that results in one or more of the following: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CHENODAL

---

## Products Affected

- Chenodal

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Pregnancy (X), Liver Dysfunction, Bile Duct abnormalities, Nonvisualizing Gallbladder after 2 single doses of dye, Radiopaque stones, Gallstone complications requiring surgery
<b>Required Medical Information</b>	Ultrasonograms, stone description, LFTs, reason why patient is not a candidate for surgery, Trial and failure, contraindication, or intolerance to Ursodiol
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gastroenterologist
<b>Coverage Duration</b>	Initial: 6 months, Reauth: 6 months if condition warrants continuation
<b>Other Criteria</b>	N/A



# CHOLBAM

---

## Products Affected

- Cholbam

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of bile acid synthesis defect due to single enzyme defect or disorder of peroxisomal function, with liver disease manifestations, steatorrhea, or complications due to decreased absorption of fat soluble vitamins
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A

# CHORIONIC GONADOTROPINS

---

## Products Affected

- Chorionic Gonadotropin INJ
- Novarel
- Pregnyl
- Pregnyl W/diluent Benzyl Alcohol/nacl

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Diagnosis or use in ovulation induction
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Prior authorization is required to ensure appropriate Part D use.

# CIMZIA

## Products Affected

- Cimzia

- Cimzia Starter Kit

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS)(Initial): Diagnosis of active ankylosing spondylitis. One of the following: A) Trial/failure, contraindication, or intolerance to TWO of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept) (etanercept) OR Humira (adalimumab) (adalimumab), 4) Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy if within the past 120 days. Crohn's (CD)(Initial): Diagnosis of moderately to severely active Crohn's disease with One of the following: Frequent diarrhea and abdominal pain, At least 10% weight loss, Complications such as obstruction, fever, abdominal mass, Abnormal lab values (e.g., CRP), CD Activity Index (CDAI greater than 220) . One of the following: A) Trial/ failure, contraindication or intolerance to BOTH Humira (adalimumab) AND Stelara (ustekinumab), OR B) For continuation of prior therapy if within the past 120 days. Non-Radiographic Axial Spondyloarthritis (NR-AXSPA)(Initial): Diagnosis of non-radiographic axial spondyloarthritis, patient has signs of inflammation, AND a minimum duration of one month trial/failure, contraindication, or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Psoriasis (PSO)(Initial): Diagnosis of moderate to severe plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement, AND One of the following: A) Trial/failure, contraindication, or intolerance to TWO of the following: 1) Cosentyx (secukinumab), 2) Skyrizi (risankizumab), 3) Enbrel (etanercept) (etanercept), 4) Humira (adalimumab), 5) Stelara (ustekinumab), OR B) For continuation of prior therapy if within the past 120 days.
<b>Age Restrictions</b>	18 years or older

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Dermatologist, Gastroenterologist, or Rheumatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>Psoriatic Arthritis (PSA)(Initial): Diagnosis of active psoriatic arthritis with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement, AND One of the following: A) TF/C/I to TWO of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Rinvoq (upadacitinib), 5) Skyrizi (risankizumab), 6) Stelara (ustekinumab), 7) Xeljanz/Xeljanz Xr (tofacitinib) OR B) For continuation of prior therapy within the past 120 days. Rheumatoid Arthritis (RA)(Initial): Diagnosis of moderately to severely active RA. One of the following: A) Trial/failure, contraindication, or intolerance to TWO of the following: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy if within the past 120 days.</p> <p>(Reauth): Documentation of positive clinical response to therapy as evidenced by improvement from baseline</p>

# CINRYZE

## Products Affected

- Cinryze

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis (labs on two separate dates) based on evidence of a normal C1 level and a low C4 level (C4 less than 14mg/dL, normal range 14-40 mg/dL, or C4 below the lower limit of normal as defined by the laboratory performing the test) plus: a low C1 Inhibitor (C1INH) antigenic level (C1INH less than 19 mg/dL normal range 19-37 mg/dL, or C1INH antigenic level below the lower limit of normal as defined by the laboratory performing the test) or a normal C1INH antigenic level (C1INH greater than 18mg/dL) and a low C1INH functional level (functional C1INH less than 50%, or below the lower limit of normal as defined by the laboratory performing the test)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# COSELA

## Products Affected

- Cosela

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of extensive-stage small cell lung cancer (ES-SCLC). Patient is receiving one of the following anti-cancer chemotherapeutic regimens: platinum/etoposide-containing regimen or topotecan-containing regimen. Infusion is completed within 4 hours prior to the start of chemotherapy. The interval between doses on sequential days will not be greater than 28 hours.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist/oncologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# COSENTYX

## Products Affected

- Cosentyx
- Cosentyx Sensoready Pen
- Cosentyx Unoready

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): Diagnosis of AS with a minimum duration of a one-month TF/C/I to one nonsteroidal anti-inflammatory drug (NSAID) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Enthesitis-Related Arthritis (ERA): Diagnosis of ERA with TF/C/I to TWO non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, meloxicam, naproxen). Non-Radiologic Axial Spondyloarthritis (NR-AXSPA): Diagnosis of NR-AXSPA. Patient has signs of inflammation (e.g., C-reactive protein [CRP] levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints.), AND a minimum duration of one month trial/failure, contraindication, or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Psoriasis (PSO): Diagnosis of moderate to severe plaque psoriasis. Documentation that the patient has chronic moderate or severe plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement, AND Minimum duration of a 4-week TF/C/I to one of the following topical therapies: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar. Psoriatic Arthritis (PSA): Diagnosis of active PSA. with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement
<b>Age Restrictions</b>	(ERA): 4 years or older. (PSA): 2 years or older. (PSO): 6 years or older. All other indications: 18 years or older.

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy as evidenced by improvement from baseline



# CRESEMBA

---

## Products Affected

- Cresemba

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concomitant use with CYP3A4 inhibitors or inducers
<b>Required Medical Information</b>	Documented Diagnosis of Invasive Aspergillosis with trial, failure, contraindication, or intolerance to voriconazole or diagnosis of invasive mucormycosis
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Infectious Disease Specialist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A

# CRINONE

---

## Products Affected

- Crinone

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	All indications: excluded if for fertility uses.
<b>Required Medical Information</b>	Secondary Amenorrhea: Diagnosis of Secondary Amenorrhea (the absence of menses in women who have already started menstruation who are not pregnant, breastfeeding, or in menopause).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CRYSVITA

---

## Products Affected

- Crysvida

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of X-Linked Hypophosphatemia confirmed by genetic testing or elevated serum FGF23 and one of the following: Epiphyseal plate has not fused or Epiphyseal plate has fused and patient is experiencing clinical signs/symptoms and failure, intolerance, or contraindication to treatment with calcitriol in combination with an oral phosphate agent. Documented fasting serum Phos level below normal range for age
<b>Age Restrictions</b>	1 year or older
<b>Prescriber Restrictions</b>	Endocrinologist or Specialist experienced in the treatment of Metabolic Bone Disorders
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 12 months.
<b>Other Criteria</b>	Reauth: Documentation of normalization of serum phosphate and a positive clinical response to therapy

# CYCLOBENZAPRINE

## Products Affected

- Cyclobenzaprine Hydrochloride TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Fibromyalgia
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For Fibromyalgia must have trial, failure, contraindication, or intolerance to at least two of the following: duloxetine, gabapentin, pregabalin, formulary antidepressants, formulary anticonvulsants, or tramadol.
<b>Age Restrictions</b>	PA applies to patients 65 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Fibromyalgia: 12 months. All other indications: 3 months
<b>Other Criteria</b>	Provider must submit attestation that benefit outweighs risk of drugs found to be high risk medications for beneficiaries age 65 and older.

# CYSTADROPS

---

## Products Affected

- Cystadrops

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Cystinosis: Diagnosis of Cystinosis, confirmed by elevated Leukocyte Cystine Levels (LCL), genetic analysis of the CTNS Gene or Corneal Cystine Crystal Accumulation
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CYSTAGON

---

## Products Affected

- Cystagon

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Nephropathic Cystinosis confirmed by the presence of increased Cystine concentration in Leukocytes or by DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CYSTARAN

---

## Products Affected

- Cystaran

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Corneal Cysteine Crystal Accumulation Cystinosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to Cystaran therapy

# DALFAMPRIDINE

## Products Affected

- Dalfampridine Er

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Seizures, renal impairment with a CrCL less than 50 mL/min or wheelchair bound
<b>Required Medical Information</b>	Baseline Timed 25-foot walk completed within 8-45 seconds, patient must be currently ambulatory. Continuation approval based on results of timed 25-foot walk or statement of clinical improvement.
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 12 months (based on therapeutic response)
<b>Other Criteria</b>	Pt must be ambulatory with no history of seizures



# DEFERASIROX

## Products Affected

- Deferasirox TBSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Under 2 years old, severe renal insufficiency, hepatitis, if on any other iron chelation therapy concomitantly
<b>Required Medical Information</b>	Covered for Transfusional Iron Overload when the patient has a Serum Ferritin level greater than 1000mcg/L and discontinuation when levels are below 500mcg/L in two consecutive months. Covered for Non-Transfusion Dependent Thalassemia Syndrome with documentation of an LIC of at least 5mg Fe/G DW and serum ferritin greater than 300mcg/L and discontinuation when levels are below 300mcg/L in two consecutive months. For all indications, patient should have documentation of auditory and ophthalmic testing prior to starting deferasirox treatment.
<b>Age Restrictions</b>	2 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A

# DEFEROXAMINE

---

## Products Affected

- Deferoxamine Mesylate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Iron toxicity, acute, iron overload, chronic, due to transfusion-dependent anemias
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# DIACOMIT

---

## Products Affected

- Diacomit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of seizures associated with Dravet Syndrome (DS). Used in combination with clobazam.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve for continuation of prior therapy

# DOPTELET

## Products Affected

- Doptelet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Thrombocytopenia Prior to Planned Procedure (TPPP): Diagnosis of Thrombocytopenia. Patient has chronic liver disease and is scheduled to undergo a procedure. Baseline platelet count is less than 50,000/MCL. Chronic Immune Thrombocytopenia (ITP): Diagnosis of Chronic Immune (idiopathic) Thrombocytopenic Purpura (ITP) or Relapsed/Refractory ITP. Baseline platelet count is less than 30,000/MCL. Trial and failure, contraindication, or intolerance to at least one of the following: corticosteroids, immunoglobulins, splenectomy, or Rituxan (rituximab). Patient's degree of Thrombocytopenia and clinical condition increase the risk of bleeding.
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	TPPP: 1 month. ITP: 12 months
<b>Other Criteria</b>	ITP (Reauth): Documentation of positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.

# DOXERCALCIFEROL

---

## Products Affected

- Doxercalciferol

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Doc Secondary Hyperparathyroidism and Stage 3, 4, or 5 CKD and trial and failure, intolerance, or contraindication to calcitriol or paricalcitol.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Endocrinologist or Nephrologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# DUPIXENT

## Products Affected

- Dupixent

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Atopic Dermatitis: Diagnosis of moderate to severe Atopic Dermatitis with One of the following: Involvement of at least 10% body surface area (BSA), SCORing Atopic Dermatitis (SCORAD) index value of at least 25. TF/C/I of a minimum 30-day supply (14-day supply for topical corticosteroids), to at least one of the following: Medium or higher potency topical corticosteroid, Pimecrolimus cream, Tacrolimus ointment, Eucrisa (crisaborole) ointment. Eosinophilic Asthma: Diagnosis of moderate to severe Eosinophilic Phenotype Asthma defined by a baseline (pre-treatment) peripheral blood eosinophil level greater than or equal to 150 cells per microliter. Corticosteroid Dependent Asthma: Diagnosis of moderate to severe Asthma. Documentation that patient is currently dependent on oral corticosteroids for the treatment of asthma. Eosinophilic Asthma, Corticosteroid Dependent Asthma: unless contraindicated, documented concurrent use of an inhaled corticosteroid and one additional asthma controller medication (e.g. Leukotriene Receptor Antagonist, Long-Acting Beta-2 Agonist, Long-Acting Muscarinic Antagonist). Rhinosinusitis with Nasal Polyposis: Diagnosis of Rhinosinusitis with Nasal Polyposis. Documented trial and failure, intolerance, or contraindication to one intranasal glucocorticoid and one oral glucocorticoid. Eosinophilic Esophagitis (EoE): Diagnosis of EoE confirmed by biopsy. Patient weighs at least 40 kg. PRURIGO NODULARIS: TF/C/I to one medium or higher potency topical corticosteroid.
<b>Age Restrictions</b>	Asthma: 6 years or older. Atopic Dermatitis: 6 months or older. Rhinosinusitis with Nasal Polyposis: 18 years or older. EoE: 12 years or older
<b>Prescriber Restrictions</b>	Dermatologist, Allergist, Immunologist, Pulmonologist, Otolaryngologist, Gastroenterologist

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (AD) Documentation of a positive clinical response to therapy.

# ELAPRASE

---

## Products Affected

- Elaprase

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme assay demonstrating deficiency of Iduronate 2-sulfatase enzyme activity or DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For patients with Hunter Syndrome (MPS II)



# ELELYSO

---

## Products Affected

- Elelyso

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented of Type 1 Gauchers Disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# ELITEK

---

## Products Affected

- Elitek

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Previous reaction to Elitek, Glucose 6-Phosphate Deficiency (G6PD)
<b>Required Medical Information</b>	Diagnosis of cancer, elevated Uric Acid levels, Tumor Lysis Syndrome. Documentation that medication was initiated while in the hospital.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	N/A

# EMGALITY

## Products Affected

- Emgality

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	<p>Episodic Migraines (EM) (120 mg/mL strength only) (initial): Diagnosis of EM. Patient has 4 to 14 migraine days per month, but no more than 14 headache days per month. Chronic Migraines (CM) (120 mg strength/mL only) (initial): Diagnosis of CM. Medication overuse headache has been considered and potentially offending medication(s) have been discontinued. Patient has greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months. Episodic Cluster Headache (ECH) (100 mg/mL strength only) (initial): Diagnosis of episodic cluster headache. Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months. EM, CM (120 mg/mL strength only) (initial): Two of the following: a) History of failure (after at least a two month trial) or intolerance to amitriptyline or venlafaxine, OR patient has a contraindication to both amitriptyline and venlafaxine, b) History of failure (after at least a two month trial) or intolerance to divalproex sodium or topiramate, OR patient has a contraindication to both divalproex sodium and topiramate, c) History of failure (after at least a two month trial) or intolerance to one of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol, OR patient has a contraindication to all of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol, or d) History of failure (after at least a two month trial) or intolerance to candesartan, OR patient has a contraindication to candesartan. All Indications (initial): Medication will not be used in combination with another injectable CGRP inhibitor.</p>
<b>Age Restrictions</b>	ECH, MP (initial): 18 years or older.
<b>Prescriber Restrictions</b>	Neurologist, Headache Specialist, Pain Specialist

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Coverage Duration</b>	ALL indications (Initial): 6 months. All indications (Reauth): 12 months.
<b>Other Criteria</b>	EM, CM (120 mg/mL strength only) (reauth): Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity. Use of acute migraine medications (e.g., non-steroidal anti-inflammatory drugs [NSAIDs] [e.g., ibuprofen, naproxen], triptans [e.g., eletriptan, rizatriptan, sumatriptan]) has decreased since the start of CGRP therapy. CM (120 mg/mL strength only) (reauth): Patient continues to be monitored for medication overuse headache. ECH (100 mg/mL strength only) (reauth): Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity. All Indications (reauthorization): Medication will not be used in combination with another injectable CGRP inhibitor.

# EMPAVELI

## Products Affected

- Empaveli

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Paroxysmal Nocturnal Hemoglobinuria (PNH) (initial): Diagnosis of PNH. Documentation that member has received meningococcal vaccination per ACIP guidelines before starting therapy with Empaveli
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Specialist: (Oncologist, Immunologist, Hematologist)
<b>Coverage Duration</b>	PNH (initial, reauth): 12 months
<b>Other Criteria</b>	PNH (reauth): Documentation of positive clinical response to therapy (e.g., improvement in hemoglobin level, hemoglobin stabilization, decrease in the number of red blood cell transfusions).

# ENBREL

## Products Affected

- Enbrel
- Enbrel Mini
- Enbrel Sureclick

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Allergic reaction to murine proteins of humanized monoclonal antibody, patients with active infections, or latent TB
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): Diagnosis of active AS. TF/C/I to one nonsteroidal anti-inflammatory drug (NSAID) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses for at least a one-month trial. Polyarticular Juvenile Idiopathic Arthritis (PJIA): Diagnosis of moderately to severely active PJIA. Trial/failure, contraindication, or intolerance to one of the following disease modifying anti-rheumatic drugs (DMARDs): leflunomide, methotrexate. Psoriasis (PSO): Diagnosis of moderate to severe chronic plaque psoriasis with one of the following: Greater than or equal to 3% of BSA, Severe scalp psoriasis, Palmoplantar (i.e. palms, soles), facial, or genital involvement. Minimum duration of a 4wk TF/C/I of at least 1 top tx: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar. Psoriatic Arthritis (PSA): Diagnosis of active psoriatic arthritis with one of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail. Rheumatoid Arthritis (RA): Diagnosis of moderately to severely active RA. Minimum duration of a 3-month Trial/failure, intolerance, or contraindication to one disease modifying antirheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine)
<b>Age Restrictions</b>	JIA: 2 years or older. Plaque Psoriasis: 4 years or older. All other diagnoses: 18 years or older.
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Dermatologist
<b>Coverage Duration</b>	12 months

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Other Criteria</b>	MDL for Plaque Psoriasis: 50mg twice weekly for 3 months, then 50mg once weekly. MDL for all other indications: 50mg once weekly. Reauth: documentation of positive clinical response to therapy. REAUTH: (ALL) Documentation of positive clinical response to therapy as evidenced by improvement from baseline
-----------------------	--

# EPCLUSA

---

## Products Affected

- Epclusa

- Sofosbuvir/velpatasvir

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Epclusa (Sofosbuvir-Velpatasvir) will not be covered for patients that are requesting Epclusa (Sofosbuvir-Velpatasvir) in combination with another HCV direct acting antiviral agent
<b>Required Medical Information</b>	Sub of medical records doc a diagnosis of Chronic Hep C Virus. Criteria will be applied consistent with current AASLD-IDSA guidance.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Hepatologist, Gastroenterologist, Infectious Disease Specialist, HIV Specialist
<b>Coverage Duration</b>	Approval period will be consistent with current AASLD/IDSA guidelines
<b>Other Criteria</b>	N/A



# EPIDIOLEX

---

## Products Affected

- Epidiolex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Lennox-Gastaut Syndrome (LGS): Diagnosis of seizures associated with LGS. Trial and failure, contraindication, or intolerance to two formulary anticonvulsants (e.g. topiramate, lamotrigine, valproate). Dravet Syndrome (DS): Diagnosis of seizures associated with DS and trial and failure, contraindication, or intolerance to two formulary anticonvulsants (e.g. topiramate, clobazam, valproate).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve for continuation of prior therapy

# EPOETIN

---

## Products Affected

- Epogen INJ 10000UNIT/ML, 20000UNIT/ML, 2000UNIT/ML, 3000UNIT/ML, 4000UNIT/ML
- Procrit
- Retacrit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Adequate iron stores shown by Serum Iron and Serum Ferritin within normal range
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision.

# EPOPROSTENOL

## Products Affected

- Epoprostenol Sodium

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with hypersensitivity to Prostacyclin analogs, high risk of hemorrhage (e.g. active peptic ulcers, trauma, intracranial hemorrhage), severe coronary heart disease, unstable angina, MI within the last 6 months, decompensated cardiac failure not under close medical supervision, severe arrhythmias, cerebrovascular events within the last 3 months, pulmonary hypertension caused by venous occlusive disease, pregnant patients.
<b>Required Medical Information</b>	Previous medications used, results of acute vasoreactivity testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. For the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II, III, or IV symptoms and for patients who have tried and failed, intolerance or contraindication (e.g. unstable patients or those with severe right heart failure) to conventional therapies, including oral anticoagulants, diuretics, supplemental oxygen, and/or digoxin.

# ESBRIET

---

## Products Affected

- Esbriet

- Pirfenidone

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Idiopathic Pulm Fibrosis. Documented baseline liver function tests.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Pirfenidone will have MDL of 270 caps per 30 days.

# EXONDYS 51

---

## Products Affected

- Exondys 51

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Excluded if member is not able to remain ambulatory (e.g. able to walk with assistance, not wheelchair dependent)
<b>Required Medical Information</b>	Diagnosis of Duchenne Muscular Dystrophy with confirmed mutation of the Dystrophin Gene Amenable to Exon 51 skipping
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Specialist in the treatment of Duchenne Muscular Dystrophy
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 6 months.
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy and documentation that member is still ambulatory

# FABRAZYME

---

## Products Affected

- Fabrazyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme assay demonstrating deficiency of alpha-galactosidase enzyme assay or DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For use in patients with Fabry Disease

# FINTEPLA

---

## Products Affected

- Fintepla

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Dravet Syndrome: Diagnosis of Dravet Syndrome. Documented trial and failure, contraindication, or intolerance to at least one formulary generic anticonvulsant (e.g. valproate, valproic acid, clobazam, topiramate). Lennox-Gastaut Syndrome: Diagnosis of seizures associated with Lennox-Gastaut syndrome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# GALAFOLD

---

## Products Affected

- Galafold

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Fabry Disease with an amendable GLA variant
<b>Age Restrictions</b>	16 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 12 months.
<b>Other Criteria</b>	FD (Reauth): Documentation of positive clinical response to Galafold therapy



# GATTEX

---

## Products Affected

- Gattex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Short Bowel Syndrome with dependence on parenteral support for at least 12 months
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gastroenterologist
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 6 months.
<b>Other Criteria</b>	Reauth: Documentation that the member has had a reduction in weekly parenteral nutrition/intravenous (PN/IV) support from baseline while on therapy

# GROWTH HORMONE

---

## Products Affected

- Lanreotide Acetate
- Norditropin Flexpro
- Omnitrope
- Serostim INJ 4MG, 5MG, 6MG
- Somatuline Depot
- Somavert

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	GH Simulation tests, HT
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Endocrinologist, Oncologist, Infectious Disease Specialist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# HAEGARDA

---

## Products Affected

- Haegarda

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Hereditary Angioedema (HAE) confirmed using Serum Complement Factor 4 (C4), CI Inhibitor (C1NH) Antigenic, and C1NH Functional levels (if available) taken at different times (second test confirms diagnosis)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# HARVONI

---

## Products Affected

- Harvoni

- Ledipasvir/sofosbuvir

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Chronic Hepatitis C Virus Genotype 1a, 1b, 4, 5, or 6 including patients with decompensated liver disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gastroenterologist, Infectious Disease Specialist, Hepatologist
<b>Coverage Duration</b>	Coverage duration will follow recommendation set forth by the AASLD
<b>Other Criteria</b>	N/A

# HETLIOZ

---

## Products Affected

- Hetlloz
- Hetlloz Lq
- Tasimelteon

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Non-24-Hour Sleep-Wake Disorder (Non-24) (initial): Both of the following: 1) Diagnosis of non-24-hour sleep-wake disorder (also known as free-running disorder, free-running or non-entrained type circadian rhythm sleep disorder, or hypernychthemeral syndrome), AND 2) patient is totally blind (has no light perception). Smith-Magenis Syndrome (SMS) (initial): Diagnosis of Smith-Magenis Syndrome (SMS). Patient is experiencing nighttime sleep disturbances (i.e., difficulty falling asleep, frequent nighttime waking and early waking).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 12 months.
<b>Other Criteria</b>	N/A

# HRM - ANTIHISTAMINES

## Products Affected

- Diphenhydramine Hcl ELIX
- Hydroxyzine Hcl TABS 50MG
- Hydroxyzine Hydrochloride TABS 10MG, 25MG
- Hydroxyzine Pamoate CAPS
- Promethazine Hcl TABS 12.5MG
- Promethazine Hydrochloride TABS 25MG, 50MG

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Nausea: Diagnosis of Nausea and trial and failure, contraindication, or intolerance to ondansetron or prochlorperazine. Hives/Itching: Trial and failure, contraindication, or intolerance to a non-sedating antihistamine (e.g. desloratadine or levocetirizine). Anxiety: Trial and failure, contraindication, or intolerance to at least two of the following: escitalopram, sertraline, duloxetine, or buspirone.
<b>Age Restrictions</b>	PA applies to patients 65 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Anxiety: 12 months: All others: 3 months
<b>Other Criteria</b>	Provider must submit attestation that benefit outweighs risk of drugs found to be high risk medications for beneficiaries age 65 and older.

## HRM - CNS, OTHER

---

### Products Affected

- Meprobamate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The drug is being prescribed for an FDA-Approved indication and the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
<b>Age Restrictions</b>	PA applies to patients 65 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# HUMIRA

---

## Products Affected

- Adalimumab-adaz
- Amjevita INJ 40MG/0.8ML
- Hadlima
- Hadlima Pushtouch
- Humira INJ 10MG/0.1ML, 20MG/0.2ML, 40MG/0.4ML, 40MG/0.8ML
- Humira Pediatric Crohns Disease Starter Pack INJ 0, 80MG/0.8ML
- Humira Pen
- Humira Pen-cd/uc/hs Starter
- Humira Pen-pediatric Uc Starter Pack
- Humira Pen-ps/uv Starter

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Patients with active infections or latent TB or symptomatic or deteriorating CHF.



<b>Required Medical Information</b>	<p>Ankylosing Spondylitis (AS)(Initial): Diagnosis of active AS. Minimum duration of a one-month Trial/failure, contraindication, or intolerance (TF/C/I) to one nonsteroidal anti-inflammatory drug (NSAID) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Crohn's (CD): Diagnosis of moderately to severely active CD with One fo the following: frequest diarrhea and abdominal pain, at least 10% weight loss, complications such as obstruction, fever, abdominal mass, abnormal lab values (e.g., CRP), CD Activity Index (CDAI greater than 220). TF/C/I to one of the following conventional therapies: corticosteroid, immunosupp (e.g. azathioprine, 6-MP, methotrexate). Hidradenitis Suppurativa (HS)(Initial): Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III). Polyarticular Juvenile Idiopathic Arthritis (PJIA)(Initial): Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis. Minimum duration of a 6-week TF/C/I to one of the following disease modifying anti-rheumatic drugs (DMARDs) at maximally indicated doses: leflunomide, methotrexate. Psoriasis (PSO)(Initial): Diagnosis of moderate to severe chronic plaque psoriasis with Doc of one of the following: Greater than or equal to 3% of BSA, severe scalp psoriasis, palmoplantar (i.e., palms, soles), facial, or genital involvement. Minimum duration of a 4-week TF/C/I to one of the following topical therapies: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D anaologs (e.g., calcitriol, calcipotriend), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal Tar. Psoriatic Arthritis (PSA)(Initial): Diagnosis of active PsA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement.</p>
<b>Age Restrictions</b>	<p>Crohn's: 6 years and older. JIA and Uveitis: 2 years and older. Hidradenitis Suppurativa: 12 years and older. UC: 5 years and older. All other diagnoses: 18 years and older.</p>
<b>Prescriber Restrictions</b>	<p>Prescribed by or in consultation with a Rheumatologist, Dermatologist, Gastroenterologist, Ophthalmologist</p>
<b>Coverage Duration</b>	<p>12 months</p>

<b>Other Criteria</b>	<p>Rheumatoid Arthritis (RA)(Initial): Diagnosis of moderately to severely active RA with a Minimum duration of a 3-month TF/C/I to one disease modifying antirheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine) at maximally indicated doses. Ulcerative Colitis (UC)(Initial): Diagnosis of moderately to severely active UC with One of the following: Greater than 6 stools per day, Frequent blood in the stools, Frequent urgency, Presence of ulcers, Abnormal lab values (e.g., hemoglobin, ESR, CRP), Dependent on, or refractory to, corticosteroids . TF/C/I to a corticosteroid, immunosuppressant, or aminosalicylates (e.g. azathioprine, 6-MP, methotrexate, mesalamine, olsalazine, or azathioprine). Uveitis(Initial): Diagnosis of non-infectious uveitis and classified as intermediate, posterior, or panuveitis. Fail of ophthalmic corticosteroid.</p> <p>Reauth (ALL): Documentation of positive clinical response to therapy as evidenced by improvement from baseline</p>
-----------------------	---

# ICATIBANT

## Products Affected

- Icatibant Acetate

- Sajazir

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis with labs on two separate dates based on evidence of a normal C1 level in the range of 14 to 40mg/dl and a low C4 level of less than or equal to 14mg/dl as defined by the laboratory performing the test plus a low C1 Inhibitor (C1INH) Antigenic level less than or equal to 19mg/dl normal range 19-37mg/dl, or C1INH Antigenic level below the lower limit of normal as defined by the laboratory performing the test, or a normal C1INH Antigenic level greater than or equal to 19mg/dl and a low C1INH functional level less than or equal to 50%, or below the lower limit of normal as defined by the laboratory performing the test and member must be experiencing at least one symptom of the moderate or severe attack, for example airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documentation of diagnosis of Hereditary Angioedema

# ILARIS

## Products Affected

- Ilaris INJ 150MG/ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	(Initial, Reauth): Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors [e.g., Enbrel (etanercept) (etanercept), Humira (adalimumab) (adalimumab), Remicade (infliximab)]. Patient is not receiving concomitant treatment with Interleukin-1 inhibitors [e.g., Arcalyst (rilonacept), Kineret (anakinra)].
<b>Required Medical Information</b>	Systemic Juvenile Idiopathic Arthritis (SJIA): Diagnosis of active systemic juvenile idiopathic arthritis. Documented trial/failure, contraindication, or intolerance to ONE of the following Conventional therapies at maximally indicated doses: Minimum duration of a 1-month trial of nonsteroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen), OR Minimum duration of a 2-week trial of Corticosteroids (e.g., methylprednisolone, prednisone), OR Minimum duration of a 3-month trial and failure of Methotrexate.
<b>Age Restrictions</b>	2 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (SJIA) Documentation of positive clinical response to therapy as evidenced by at least one of the following: Reduction in the total active (swollen and tender) joint count from baseline, Improvement in clinical features or symptoms (e.g., pain, fever, inflammation, rash, lymphadenopathy, serositis) from baseline

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# INCRELEX

## Products Affected

- Increlex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with closed epiphyses, patients with active or suspected neoplasia
<b>Required Medical Information</b>	Height Measurements and Serum IGF-1 levels three or more STD deviations below normal (based on lab reference range for age and sex), and normal or elevated Growth Hormone levels
<b>Age Restrictions</b>	2 years or older
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Discontinuation occurs when linear growth ceases

# INFLIXIMAB

## Products Affected

- Avsola
- Inflectra
- Infliximab
- Remicade
- Renflexis

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	<p>Ankylosing Spondylitis (AS)(Initial): Diagnosis of active AS with a minimum duration of a one-month Trial and failure, contraindication, or intolerance to one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab. Crohn's Disease (CD)(Initial): Diagnosis of moderately to severely active CD OR Fistulizing Crohn's disease (FCD) with One of the following: Frequent diarrhea and abdominal pain, At least 10% weight loss, Complications such as obstruction, fever, abdominal mass, Abnormal lab values (e.g., CRP), CD Activity Index (CDAI greater than 220). TF/C/I to one of the following: corticosteroid or immunosuppressant (azathioprine, 6-MP, or methotrexate) therapy. Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab. Psoriasis (PSO)(Initial): Doc that pt has chronic sev plaque psoriasis (i.e., extensive and/or disabling) with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement, AND Minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar. Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab. Psoriatic Arthritis (PSA)(Initial): Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement. Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab.</p>
Age Restrictions	N/A

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist, Gastroenterologist, Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>Rheumatoid Arthritis (RA)(Initial): Diagnosis of moderately to severely active RA AND used in combination with methotrexate. Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab. Documentation of failure to respond to a 2 month trial of Enbrel (etanercept) or Humira (adalimumab) or an intolerance of or contraindication to Enbrel (etanercept) or Humira (adalimumab). Must have concurrent treatment with MTX OR trial/failure/intolerance/contra. All dose incr after initial tx must be prior auth'd. Ulcerative Colitis (UC)(Initial): Use for moderately to severely active UC with One of the following: Greater than 6 stools per day, Frequent blood in the stools, Frequent urgency, Presence of ulcers, Abnormal lab values (e.g., hemoglobin, ESR, CRP), Dependent on, or refractory to, corticosteroids . Trial/failure, intolerance, or contraindication to a corticosteroid, immunosuppressant, or aminosalicylates (e.g. azathioprine, 6-MP, methotrexate, mesalamine, osalazine, sulfasalazine). Avsola, Inflectra, and Renflexis only: Trial and failure or intolerance to Remicade or Infliximab</p> <p>Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline. All indications: TB screening</p>

# INGREZZA

---

## Products Affected

- Ingrezza

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of Tardive Dyskinesia
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist, Psychiatrist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	QL: 60 tablets per 30 days



# ISOTRETINOIN

## Products Affected

- Accutane
- Amnesteem
- Claravis
- Isotretinoin CAPS
- Myorisan
- Zenatane

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Acne: Diagnosis of Acne. Trial and failure, contraindication, or intolerance to an adequate trial (at least 30 days) on both of the following conventional therapy regimens: A) Topical retinoid or retinoid-like agent (e.g. Retin-A/Retin-A Micro [tretinoin]) and one of the following: B) Oral antibiotic (e.g. Ery-Tab [erythromycin], Minocin [minocycline]) or Adapalene
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Dermatologist
<b>Coverage Duration</b>	Acne: 5 months.
<b>Other Criteria</b>	Reauth: One of the following: A) After more than 2 months off therapy, persistent or recurring severe recalcitrant nodular acne is still present, or B) the total cumulative dose is less than 150mg/kg (will be approved up to a total of 150mg/kg).

# ISTURISA

---

## Products Affected

- Isturisa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Cushing's disease (initial): Diagnosis of Cushing's disease. One of the following: a) Patient is not a candidate for pituitary surgery, OR b) Pituitary surgery has not been curative for the patient.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Cushing's disease (reauth): Documentation of positive clinical response to therapy (e.g., a clinically meaningful reduction in 24-hour urinary free cortisol levels, improvement in signs or symptoms of the disease).

# IVERMECTIN

---

## Products Affected

- Ivermectin TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Strongyloidiasis: Diagnosis of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite <i>Strongyloides stercoralis</i> OR both of the following: member received the drug within the past 120 days and member requires continuation of therapy. Onchocerciasis: Diagnosis of onchocerciasis due to the nematode parasite <i>Onchocerca volvulus</i> OR both of the following: member received the drug within the past 120 days and member requires continuation of therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Strongyloidiasis: 3 weeks. Onchocerciasis: 6 months.
<b>Other Criteria</b>	N/A

# JAKAFI

## Products Affected

- Jakafi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Intermediate or High-Risk Myelofibrosis (Myelofibrosis diagnosis includes Primary, Postpolycythemia, and Postessential Thrombocythemia Myelofibrosis). Diagnosis of Polycythemia Vera with trial and failure, contraindication, or intolerance to hydroxyurea. Diagnosis of Steroid-Refractory Acute Graft-Versus-Host Disease. Diagnosis of chronic graft versus host disease (cGVHD). Trial and failure of at least one or more lines of systemic therapy (e.g., corticosteroids, mycophenolate, etc.).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# JUXTAPID

## Products Affected

- Juxtapid CAPS 10MG, 20MG, 30MG, 5MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concomitant use with mod or strong CYP3A4 inhibitors, hepatic impairment, mod or sev (Child-Pugh cat B or C), liver disease, active, including unexplained persistent elevations of serum transaminases, pregnancy
<b>Required Medical Information</b>	Diagnosis of Homozygous Familial Hypercholesterolemia, liver function tests, and negative pregnancy test in women with reproductive potential
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Endocrinologist, Cardiologist
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 6 months
<b>Other Criteria</b>	N/A

# JYNARQUE

---

## Products Affected

- Jynarque

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hypovolemia, hypernatremia: use in patients unable to sense or appropriately respond to thirst, clinically relevant hepatic impairment, anuria, pregnancy, or breastfeeding.
<b>Required Medical Information</b>	Diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# KALBITOR

## Products Affected

- Kalbitor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis (labs on two separate dates) based on evidence of a normal C1 level and a low C4 level (C4 less than 14mg/dl, normal range 14-40 mg/dL, or C4 below the lower limit of normal as defined by the laboratory performing the test) plus: a low C1 Inhibitor (C1INH) antigenic level (C1INH less than 19mg/dL normal range 19-37mg/dL, or C1INH antigenic level below the lower limit of normal as defined by the laboratory performing the test) or a normal C1INH antigenic level (C1INH greater than 18mg/dL) and a low C1INH functional level (functional C1INH less than 50%, or below the lower limit of normal as defined by the laboratory performing the test)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Confirmed diagnosis of HAE and member must be experiencing at least one symptom of the moderate or severe attack (e.g. airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion).

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# KALYDECO

---

## Products Affected

- Kalydeco

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of CF in patients who have one mutation in the CFTR gene that is responsive to Ivacaftor Potentiation
<b>Age Restrictions</b>	Patient is 1 month of age or older
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# KANUMA

---

## Products Affected

- Kanuma

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented Diagnosis of Wolman's Disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Endocrinologist, Geneticist, Gastroenterologist, Lipidologist, Metabolic Specialist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# KEPIVANCE

---

## Products Affected

- Kepivance

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with non-hematologic malignancies
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	Subject to BvD decision.

# KERENDIA

## Products Affected

- Kerendia

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Initial: Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) defined by one of the following: 1) All of the following: a) urinary albumin-to-creatinine ratio (UACR) of 30 to 300 mg/g, b) estimated glomerular filtration rate (eGFR) 25 to 60 mL/min/1.73 m <sup>2</sup> , and c) diabetic retinopathy, OR 2) Both of the following: a) UACR of greater than or equal to 300 mg/g and b) eGFR of 25 to 75 mL/min/1.73 m <sup>2</sup> . One of the following: 1) Minimum 30-day supply trial of a maximally tolerated dose and will continue therapy with one of the following: a) generic angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril), or b) generic angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan), OR 2) Patient has a contraindication or intolerance to ACE inhibitors and ARBs.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial, Reauth: 12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy. One of the following: 1) Patient continues to be on a maximally tolerated dose of ACE inhibitor or ARB, OR 2) Patient has a contraindication or intolerance to ACE inhibitors and ARBs.

# KEVEYIS

---

## Products Affected

- Dichlorphenamide

- Keveyis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented Diagnosis of Primary Hyperkalemic Periodic Paralysis or Primary Hypokalemic Periodic Paralysis, or Related Variants of Primary Paralysis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist, Endocrinologist
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 12 months (with documentation of beneficial response)
<b>Other Criteria</b>	N/A

# KINERET

## Products Affected

- Kineret

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hypersensitivity to proteins derived from E. coli
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): Diagnosis of moderately to severely active RA. One of the following: A) Documented trial/failure, contraindication, or intolerance to two of the following products: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), OR B) For continuation of prior therapy if within the past 120 days.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist, Dermatologist, Neurologist, Pediatrician
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline.

# KORLYM

## Products Affected

- Korlym

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Type 2 Diabetes Mellitus unrelated to endogenous Cushings, Pregnancy, Use of simvastatin or lovastatin and CYP3A substrates with narrow therapeutic range, Concurrent long-term corticosteroid use, Women w hx of unexplained vaginal bleeding, Women w endometrial hyperplasia w atypia or endometrial carcinoma
<b>Required Medical Information</b>	Covered for indication of Controlling Hyperglycemia secondary to Hypercortisolism in adult patients with endogenous Cushings Syndrome who have Type 2 Diabetes Mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# KRYSTEXXA

---

## Products Affected

- Krystexxa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Anaphylaxis and infusions reactions (boxed warning), contraindication in pt w/G6PD deficiency due to risk of hemolysis and methemoglobinemia, Gout flares during initiation of treatment
<b>Required Medical Information</b>	Documentation of Chronic Gout in adult patients refractory to conventional therapy and 3 month trial of XO Inhibitor (e.g. allopurinol, febuxostat).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# KUVAN

## Products Affected

- Sapropterin Dihydrochloride

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial: 2 months. Reauth: 3 months
<b>Other Criteria</b>	Prior authorization is to monitor if patient is a responder or nonresponder after therapy has been initiated for 2 months. If phenylalanine levels have decreased after the 2 months, then authorization will continue.



# LAZANDA

---

## Products Affected

- Lazanda SOLN 100MCG/ACT, 400MCG/ACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Opioid non-tolerant patients
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# LEMTRADA

## Products Affected

- Lemtrada

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (e.g. Relapsing-Remitting MS, Secondary-Progressive MS with relapses, Progressive-Relapsing MS with relapses). One of the following: 1) Patient has not been previously treated with alemtuzumab, and patient has had at least a 4 week trial and failure, contraindication, or intolerance to two of the following: Interferon Beta-1A (Avonex or Rebif), Interferon Beta-1B (Betaseron, Extavia), glatiramer acetate (Copaxone or Glatopa), dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), fingolimod (Gilenya), peginterferon Beta-1A (Plegridy), Natalizumab (Tysabri) or 2) Patient has previously received treatment with alemtuzumab, and at least 12 months have or will have elapsed since the first treatment with alemtuzumab, and patient has not already received the FDA-recommended lifetime limit of two treatment courses of alemtuzumab. Patient is not receiving alemtuzumab in combination with another disease modifying agent (e.g. interferon beta preparations, glatiramer acetate, natalizumab, fingolimod, or teriflunomide).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	MS: 12 months. Max: 24 months.
<b>Other Criteria</b>	N/A

# LEUKINE

## Products Affected

- Leukine INJ 250MCG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concomitant use with chemotherapy or radiotherapy or use within 24 hours
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Subject to BvD decision. Allogenic bone marrow transplantation, myeloid reconstitution in HLA-matched related donors, Autologous bone marrow transplantation, myeloid reconstitution following transplant in patients with Non-Hodgkin's Lymphoma, Hodgkin's Disease, and Acute Lymphoblastic Leukemia, bone marrow transplant, delay or failure of myeloid engraftment, febrile neutropenia, in acute myelogenous leukemia following induction chemotherapy, prophylaxis harvesting of peripheral blood stem cells, peripheral blood stem cell graft, autologous, myeloid reconstitution following transplant in patients mobilized with granulocyte macrophage colony stimulating factor.

# LEUPROLIDE

---

## Products Affected

- Eligard
- Leuprolide Acetate INJ 1MG/0.2ML, 22.5MG
- Lupron Depot (1-month)
- Lupron Depot (3-month)
- Lupron Depot (4-month)
- Lupron Depot (6-month)
- Lupron Depot-ped (1-month)
- Lupron Depot-ped (3-month)
- Lupron Depot-ped (6-month)

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Subject to BvD decision. Leuprolide acetate injection is indicated in the tx of advanced or metastatic prostate cancer, tx of children with Central Precocious Puberty, endometriosis and uterine leiomyomata (fibroids).

# LIDOCAINE

---

## Products Affected

- Lidocaine PTCH 5%

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of Post-herpetic Neuropathy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# LUMIZYME

---

## Products Affected

- Lumizyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme testing that demonstrates reduced GAA enzyme activity or by DNA testing for mutations in the GAA gene.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# LUPKYNIS

---

## Products Affected

- Lupkynis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Lupus Nephritis (initial): Diagnosis of active lupus nephritis. Used in combination with immunosuppressive therapy (e.g., mycophenolate mofetil, methylprednisolone).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Lupus Nephritis (initial): Prescribed by or in consultation with a nephrologist or rheumatologist
<b>Coverage Duration</b>	Lupus Nephritis (initial, reauth): 12 months
<b>Other Criteria</b>	Lupus Nephritis (reauth): Documentation of positive clinical response to therapy.

# MAVENCLAD

## Products Affected

- Mavenclad

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Current malignancy, current pregnancy, breastfeeding, or men or women of reproductive potential who do not plan to use effective contraception during therapy and for 6 months after the last dose in each treatment course, HIV infection, active chronic infections (e.g., hepatitis or tuberculosis)
<b>Required Medical Information</b>	Diagnosis of Active SPMS confirmed by progress notes which show a previous RRMS course with increasing disability over the last 6 months or longer. Diagnosis of RRMS and trial and failure, contraindication, or intolerance to two previous disease modifying drugs indicated for the treatment of RRMS
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months, max 24 months
<b>Other Criteria</b>	Documentation that lymphocyte and CBC is being monitored before, during and after treatment. QL up to 10 tablets per 5 day cycle. Max one course per year, consisting of two 4-5 day treatment cycles separated by 23 to 27 days (from last day of first cycle to first day of second cycle). Second course at least 43 weeks after the last dose of the previous year's course. FDA states that treatment beyond 2 years may further increase the risk of malignancy.



# MAVYRET

---

## Products Affected

- Mavyret

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Mavyret will not be covered for patients that are requesting Mavyret in combination with another HCV direct-acting antiviral agent
<b>Required Medical Information</b>	Documented diagnosis of Chronic Hepatitis C Virus. Criteria will be applied consistent with current AASLD-IDSA guidance
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Hepatologist, Gastroenterologist, Infectious Disease Specialist, HIV Specialist
<b>Coverage Duration</b>	Approval period will be consistent with current AASLD/IDSA guidelines
<b>Other Criteria</b>	N/A

# MEGACE

---

## Products Affected

- Megestrol Acetate SUSP 40MG/ML, 625MG/5ML
- Megestrol Acetate TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Evaluate use as a Part D covered diagnosis

# MOZOBIL

---

## Products Affected

- Mozobil

- Plerixafor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Subject to BvD decision. Harvesting of peripheral blood stem cells, in patients with Non-Hodgkin's Lymphoma and Multiple Myeloma.

# MULPLETA

---

## Products Affected

- Mulpleta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Thrombocytopenia with Chronic Liver Disease. Baseline platelet count less than 50,000 platelets/MCL
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	7 days
<b>Other Criteria</b>	Patient scheduled to undergo a medical or dental procedure expected to cause major bleeding within the next 30 days

# MYALEPT

---

## Products Affected

- Myalept

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	HIV related lipodystrophy, metabolic disease without current evidence of generalized lipodystrophy.
<b>Required Medical Information</b>	Diagnosis of Congenital or Acquired Generalized Lipodystrophy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# NAGLAZYME

---

## Products Affected

- Naglazyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme assay demonstrating deficiency of N-acetylgalactosamine 4-sulfatase (Arylsulfatase B) enzyme activity or DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For patients with MPS VI

# NATPARA

---

## Products Affected

- Natpara

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of Hypocalcemia due to Hypoparathyroidism, and documented trial and failure, contraindication, or intolerance to calcitriol
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# NEXLETOL

---

## Products Affected

- Nexletol

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Nexletol will not be covered in combination concomitant use with PCSK9 therapy
<b>Required Medical Information</b>	Documented diagnosis of established Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documented inability to achieve LDL-C goals on maximally tolerated statin therapy



# NEXLIZET

---

## Products Affected

- Nexlizet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Nexlizet will not be covered in combination concomitant use with PCSK9 therapy
<b>Required Medical Information</b>	Documented diagnosis of established Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documented inability to achieve LDL-C goals on maximally tolerated statin therapy

# NUCALA

## Products Affected

- Nucala

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of Eosinophilic Phenotype Severe Asthma. Peripheral Blood Eosinophil count of greater than or equal to 150 cells per microliter within the previous 6 weeks. Documented diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA). Documented diagnosis of hypereosinophilic syndrome (HES). Documented diagnosis of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
<b>Age Restrictions</b>	6 years or older
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Pulmonologist, Rheumatologist, Hematologist, Otolaryngologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Asthma: Documented concurrent use of an inhaled corticosteroid, and documented concurrent use of one of the following: Inhaled Long Acting Beta Agonist (Serevent, Foradil), Long Acting Anti-Muscarinic Antagonist (Tudorza, Spiriva), Leukotriene Receptor Antagonist (montelukast, zafirlukast), theophylline. EGPA: Documented failure of oral glucocorticoids.

# NUEDEXTA

---

## Products Affected

- Nuedexta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Pseudobulbar Affect
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# NUPLAZID

---

## Products Affected

- Nuplazid CAPS
- Nuplazid TABS 10MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Parkinson's Disease- Psychotic Disorder
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# NURTEC

## Products Affected

- Nurtec

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Nurtec will not be approved if it is being used in combination with another calcitonin gene-related peptide (CGRP) inhibitor (injectable or oral). Nurtec will not be approved if being used in combination with Reyvow (lasmiditan).
Required Medical Information	<p>Initial: Diagnosis of moderate/severe migraine with or without aura per International Classification of Headache Disorders. For patients with 4+ migraine days per month, doc that member is on at least 1 American Headache Society Level A or B migraine prophylactic therapy. Must be one of the following: Doc trial of at least one generic triptan therapy with little to no relief of moderate/severe migraine sx, or doc contraindication to triptan therapy defined as one of the following: 1) History of stroke/transient ischemic attack 2) History of hemiplegic or basilar migraine 3) Peripheral vascular disease, ischemic bowel disease 4) Uncontrolled hypertension 5) Recent use (within 2 weeks) of MAOI 6) Recent use (within 24 hours) of treatment with another 5-HT<sub>1</sub> Agonist, ergot-containing or ergotype medication (e.g. methysergide, dihydroergotamine) 7) Ischemic coronary artery disease (angina pectoris, history of myocardial infarction [MI], or doc silent ischemia) 8) Coronary artery vasospasm, including Prinzmetal variant angina, or other significant underlying cardiovascular disease 9) Wolff- Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders 10) Patients with risk factors for CAD (e.g. hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male 40 years of age) in whom adequate cardiac evaluation has not ruled out CAD. Preventive Treatment of Episodic Migraine (EM) (initial): Both of the following: diagnosis of EM and patient has 4 to 18 migraine days per month (no more than 18 headache days/month). Two of the following: a) TF/C/I (after 1 month trial) to amitriptyline or venlafaxine, b) TF/C/I (after 1 month trial) to divalproex sodium or topiramate, c) TF/C/I (after 1 month trial) to one of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol. Medication will not be used in combination with injectable CGRP inhibitor.</p>

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Age Restrictions</b>	Initial: 18 years or older
<b>Prescriber Restrictions</b>	Neurologist, Pain Specialist, Headache Specialist or Physician who specializes in the treatment of Chronic Migraine Management
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy (reduction in pain, photophobia, phonophobia). If the member is having 4 or more migraine headache days per month. Requests for an increase in the MDL up to the maximum FDA approved dose will be approved if the provider submits a request for a quantity exception that establishes medical necessity, including members headache diary that supports the need for an additional quantity.

# NUVIGIL

## Products Affected

- Armodafinil

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Treatment of Multiple Sclerosis
<b>Required Medical Information</b>	Diagnosis of Narcolepsy confirmed by Sleep Lab evaluation. Diagnosis of Obstructive Sleep Apnea or Hypopnea Syndrome confirmed by Polysomnography and has score of 10 or more in the Epworth Sleepiness Scale. Diagnosis of Shift-Work Sleep Disorder (SWSD) confirmed by symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, or sleep study demonstrating loss of a normal sleep-wake pattern (e.g. Disturbed Chronobiologic Rhythmicity). No other medical condition or medication accounts for they symptoms.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	OSAHS (Reauth): Documentation of positive clinical response to prior therapy. SWSD (Reauth): Documentation of positive clinical response to prior therapy. Patient still requires treatment for SWSD. Narcolepsy (Reauth): Documentation of positive clinical response to prior therapy.

# Ocaliva

---

## Products Affected

- Ocaliva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Primary Biliary Cirrhosis used in combo with ursodeoxycholic acid or as monotherapy when ursodeoxycholic acid is not tolerated
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# OCTREOTIDE

---

## Products Affected

- Octreotide Acetate INJ  
1000MCG/ML, 100MCG/ML,  
200MCG/ML, 500MCG/ML,  
50MCG/ML
- Sandostatin Lar Depot

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of Acromegaly with inadequate response to surgery or resection is not an option or inadequate response to radiation or failed bromocriptine or adjunctive tx w irradiation to help relieve sx's and possibly slow tumor growth, prophylactic treatment prior to surgery for gastrinoma
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# OFEV

## Products Affected

- Ofev

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented baseline liver function tests. Diagnosis of Idiopathic Pulmonary Fibrosis as defined by the American Thoracic Society, or diagnosis of Systemic Sclerosis Associated Interstitial Lung Disease. Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype: 1) Diagnosis of Chronic Fibrosing Interstitial Lung Disease, and 2) Patient has a High-Resolution Computed Tomography (HRCT) showing at least 10% of lung volume with fibrotic features, and 3) Disease has a Progressive Phenotype as observed by one of the following: Decline of Forced Vital Capacity (FVC), worsening of respiratory symptoms. or increased extent of fibrosis seen on imaging.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ONCOLOGY AGENTS

---

## Products Affected

- Abiraterone Acetate
- Adstiladrin
- Akeega
- Alecensa
- Alimta
- Aliqopa
- Alunbrig
- Alymsys
- Ayvakit
- Balversa
- Bavencio
- Beleodaq
- Bendamustine Hydrochloride
- Bendeka
- Besponsa
- Bexarotene CAPS
- Blincyto
- Bortezomib
- Bosulif
- Braftovi CAPS 75MG
- Brukinsa
- Cabometyx
- Calquence
- Caprelsa
- Columvi
- Cometriq
- Copiktra
- Cotellic
- Cyramza
- Dactinomycin
- Danyelza
- Darzalex
- Darzalex Faspro
- Daurismo
- Elahere
- Elrexio
- Elzonris
- Empliciti
- Enhertu
- Epkinly
- Erbitux
- Erivedge
- Erleada
- Erlotinib Hydrochloride TABS
- Everolimus TABS 10MG, 2.5MG, 5MG, 7.5MG
- Everolimus TBSO
- Evomela
- Exkivity
- Farydak
- Fotivda
- Fyarro
- Gavreto
- Gazyva
- Gefitinib
- Gilotrif
- Herceptin INJ 150MG
- Herceptin Hylecta
- Herzuma
- Ibrance
- Iclusig
- Idhifa
- Imatinib Mesylate
- Imbruvica
- Imfinzi
- Imjudo
- Infugem
- Inlyta
- Inqovi
- Inrebic
- Iressa
- Jaypirca
- Jemperli
- Kanjinti
- Keytruda INJ 100MG/4ML
- Kimmtrak
- Kisqali
- Kisqali Femara 200 Dose
- Kisqali Femara 400 Dose

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

- Kisqali Femara 600 Dose
- Koselugo
- Krazati
- Lapatinib Ditosylate
- Lenalidomide
- Lenvima 10 Mg Daily Dose
- Lenvima 12mg Daily Dose
- Lenvima 14 Mg Daily Dose
- Lenvima 18 Mg Daily Dose
- Lenvima 20 Mg Daily Dose
- Lenvima 24 Mg Daily Dose
- Lenvima 4 Mg Daily Dose
- Lenvima 8 Mg Daily Dose
- Libtayo
- Lonsurf
- Lorbreana
- Lumakras
- Lumoxiti
- Lunsumio
- Lynparza TABS
- Lytgobi
- Margenza
- Marqibo
- Matulane
- Mekinist
- Mektovi
- Melphalan Hydrochloride
- Monjuvi
- Mvasi
- Mylotarg
- Nerlynx
- Nexavar
- Ninlaro
- Nubeqa
- Odomzo
- Ogivri INJ 1.1%; 420MG, 150MG
- Ojjaara
- Ontruzant
- Opdivo
- Opdualag
- Orgovyx
- Orserdu
- Padcev
- Pazopanib Hydrochloride
- Pemazyre
- Pemetrexed
- Pemetrexed Disodium
- Pemfexy
- Perjeta
- Phesgo
- Piqray 200mg Daily Dose
- Piqray 250mg Daily Dose
- Piqray 300mg Daily Dose
- Polivy
- Pomalyst
- Portrazza
- Qinlock
- Retevmo
- Revlimid
- Rezlidhia
- Riabni
- Rituxan
- Rituxan Hycela
- Rozlytrek CAPS
- Rubraca
- Ruxience
- Rybrevant
- Rydapt
- Sarclisa
- Scemblix
- Sorafenib
- Sorafenib Tosylate TABS
- Sprycel
- Stivarga
- Sunitinib Malate
- Sylvant
- Tabloid
- Tabrecta
- Tafinlar
- Tagrisso
- Talvey
- Talzenna
- Tassigna
- Tazverik
- Tecentriq
- Tecvayli

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

- Temodar INJ
- Tepmetko
- Thiotepa INJ 100MG, 15MG
- Tibsovo
- Tivdak
- Toremifene Citrate
- Trazimera
- Treanda INJ 100MG, 25MG
- Trelstar Mixject
- Tretinoin CAPS
- Trodelvy
- Truseltiq
- Truxima
- Tukysa
- Turalio
- Ukoniq
- Vanflyta
- Vectibix INJ 100MG/5ML, 400MG/20ML
- Vegzelma
- Velcade
- Venclexta
- Venclexta Starting Pack
- Verzenio
- Vitrakvi
- Vizimpro
- Vonjo
- Votrient
- Vyxeos
- Welireg
- Xalkori
- Xospata
- Xpovio
- Xpovio 60 Mg Twice Weekly
- Xpovio 80 Mg Twice Weekly
- Xtandi
- Yervoy
- Yondelis
- Yonsa
- Zejula
- Zelboraf
- Zepzelca
- Zoladex
- Zolinza
- Zydelig
- Zykadia TABS
- Zynlonta
- Zynyz

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For requests of brand agents within this policy that have a generic available, must have trial/failure of generic agent first
<b>Age Restrictions</b>	N/A

<b>Prescriber Restrictions</b>	Ayvakit: Prescribed by or in consultation with an oncologist/hematologist, allergist, or immunologist. All others: Oncologist, Hematologist, Rheumatologist, Transplant Specialist, Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Tx of cancer type listed in an accepted compendia AHFS-DI, NCCN, Thomson Micromedex, Clinical Pharmacology, and Lexi-Drugs as outlined in the Medicare Benefit Policy Manual Ch. 15 Section 50.4.5(c). Everolimus will also be approved for a documented diagnosis of Tuberous Sclerosis Complex Associated Partial Onset Seizures. Imbruvica will also be approved for a documented diagnosis of Graft vs Host Disease. Ayvakit will also be approved for advanced systemic mastocytosis

# OPSUMIT

## Products Affected

- Opsumit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with severe anemia, Patients on strong CYP3A4 inducers (rifampin) or CYP3A4 inhibitors (ketoconazole, ritonavir), Pregnant patients
<b>Required Medical Information</b>	Documentation of previous medications used, results of acute vasoreactivity testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ORAL FENTANYL PRODUCTS

---

## Products Affected

- Fentanyl Citrate Oral Transmucosal

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented tolerance to current long acting opioid regimen and requires immediate-release breakthrough opioid. Opioid tolerance defined as pt taking at least 60mg morphine/day, 25mcg transdermal fentanyl/hr, or an equianalgesic dose of another opioid for a week or longer.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A



# ORENCIA

## Products Affected

- Orenzia

- Orenzia Clickject

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	<p>Polyarticular Juvenile Idiopathic Arthritis (PJIA): Diagnosis of moderately to severely active PJIA. One of the following: A) Trial and failure, contraindication, or intolerance to two of the following: Enbrel (etanercept), Humira (adalimumab), Xeljanz/Xeljanz XR (tofacitinib), OR B) For continuation of prior therapy if within the past 120 days. Psoriatic Arthritis (PSA): Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement. One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Rinvoq (upadacitinib), 5) Skyrizi (risankizumab), 6) Stelara (ustekinumab), 7) Xeljanz/Xeljanz XR (tofacitinib), OR B) For continuation of prior therapy within the past 120 days. Rheumatoid Arthritis (RA): Diagnosis of moderately to severely active RA. One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), OR B) For continuation of prior therapy if within the past 120 days.</p>
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline.

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# ORFADIN

---

## Products Affected

- Nitisinone
- Orfadin CAPS 20MG
- Orfadin SUSP

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmed by biochemical testing (e.g. detection of succinylacetone in urine) and appropriate clinical picture of the patient or by DNA testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Orfadin (nitisinone) is indicated in the treatment of patients with Hereditary Tyrosinemia Type 1 (HT-1)

# ORKAMBI

---

## Products Affected

- Orkambi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of CF and patients who are homozygous for the F508del mutation in the CFTR gene
<b>Age Restrictions</b>	1 year or older
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ORLADEYO

---

## Products Affected

- Orladeyo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis has been confirmed by C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by one of the following: C1-INH antigenic level below the lower limit of normal OR C1-INH functional level below the lower limit of normal, documentation that medication will be used for prophylaxis against Hereditary angioedema (HAE) attacks
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an immunologist or an allergist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# OSPHENA

## Products Affected

- OspheNa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Dyspareunia: Diagnosis of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Trial and failure, contraindication, or intolerance to one of the following: Estrace (estradiol) vaginal cream or Premarin (conjugated estrogens) vaginal cream. Vaginal Dryness: Diagnosis of vaginal dryness with trial and failure, contraindication, or intolerance to one of the following: Estrace (estradiol) vaginal cream or Premarin (conjugated estrogens) vaginal cream.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Dyspareunia and vaginal dryness (Reauth): Documentation of positive clinical response to therapy

# OTEZLA

## Products Affected

- Otezla

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Behcet Disease: Diagnosis of Behcet Disease with oral ulcers. Trial and failure, intolerance, or contraindication to colchicine. Psoriasis (PSO): Diagnosis of moderate to severe plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement AND One of the following: A) Documented trial and failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Skyrizi (risankizumab), 5) Stelara (ustekinumab) OR B) For continuation of prior therapy if within the past 120 days. Psoriatic Arthritis (PSA): Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement . One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Rinvoq (upadacitinib), 5) Skyrizi (risankizumab), 6) Stelara (ustekinumab), 7) Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy within the past 120 days.
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline.

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# OXANDROLONE

## Products Affected

- Oxandrolone TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Carcinoma of the breast in females with hypercalcemia, Carcinoma of the prostate or the male breast, Hypercalcemia, Nephrosis, Pregnancy.
<b>Required Medical Information</b>	Steps taken to avoid weight loss. Documentation of a hx of a failure to gain weight. Hx of extensive surgery, chronic infections, severe trauma, or other pathophysiological reasons for a failure to gain or maintain weight. Hx of corticosteroid use or dx of osteoporosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	Documentation of a hx of failure to gain weight due to a hx of extensive surgery, chronic infections, severe trauma, or other pathophysiological reasons for failure to gain or maintain weight or hx of long-term corticosteroid use of bone pain associated with osteoporosis.

# OXERVATE

---

## Products Affected

- Oxervate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Doc of Stage 2 or 3 neurotrophic keratitis, with decreased or absent corneal sensation, must include which eye(s) is/are affected, Doc that any ocular surface disease is currently being treated with conventional therapies (e.g. antibiotic ointments)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Ophthalmologist
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	Reauth: Documentation of recurrence of neurotrophic keratitis



## PART D VS. EXCLUDED

---

### Products Affected

- Glydo
- Imvexxy Maintenance Pack
- Imvexxy Starter Pack
- Lidocaine OINT 5%
- Lidocaine Hcl EXTERNAL SOLN 4%
- Lidocaine Hcl PRSY
- Lidocaine Hcl Jelly
- Lidocaine/prilocaine CREA
- Pliaglis CREA

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A

# PCSK9

## Products Affected

- Praluent
- Repatha
- Repatha Pushtronex System
- Repatha Sureclick

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Doc of Secondary Prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease and the patient is very high risk for future ASCVD events or one major ASCVD event and multiple high risk conditions. Triglyceride (TG) level less than 400mg/dL, LDL greater than 70mg/dL, doc failure or intolerance to high or medium intensity statin therapy. Doc of Primary Hyperlipidemia including heterozygous familial hypercholesterolemia or homozygous familial hypercholesterolemia confirmed by mutation in LDL receptor, APO B, or PCSK9 gene or a formal clinical diagnosis using US Make Early Diagnosis Prevent Early Death (MEDPED) Dutch lipid clinical network or Simon-Broome Registry, TG level less than 400mg/dL and ACC/AHA 10 year risk calculation of 7.5% or greater, LDL greater than 100mg/dL, failure or intolerance to high or medium intensity statin therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cardiologist, Endocrinologist, Lipid Specialist
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 12 months if responding to medication.
<b>Other Criteria</b>	N/A

## PH PDE5 INHIBITORS

---

### Products Affected

- Alyq
- Sildenafil INJ
- Sildenafil Citrate SUSR
- Sildenafil Citrate TABS 20MG
- Tadalafil TABS 20MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients receiving nitrates in any form, either regularly or intermittently.
<b>Required Medical Information</b>	Documented previous failure of or contraindication to a generic formulary CCB if testing reveals vasoactivity.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# PRETOMANID

---

## Products Affected

- Pretomanid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Confirmed susceptibility data that indicate member has pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Infectious Disease Specialist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Documentation that Pretomanid will be used in combination with Sirturo (bedaquiline) and linezolid.

# PROCYSBI

## Products Affected

- Procysbi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Documented allergy to penicillamine
<b>Required Medical Information</b>	Nephropathic Cystinosis: Diagnosis of Nephropathic Cystinosis, confirmed by elevated Leukocyte Cystine Levels (LCL) or genetic analysis of the CTNS Gene or demonstration of Cysteine Corneal Crystals by slit lamp examination.
<b>Age Restrictions</b>	1 year or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 6 months with documentation of WBC cystine levels
<b>Other Criteria</b>	Documentation of trial and failure of max rec dose of Cysteamine IR caps. Adolescents weighing more than 50kg, adults 1.95G/M2/Day. Doc of WBC Cystine levels greater than 1nmol half-cystine/mg protein

# PROMACTA AND NPLATE

## Products Affected

- Nplate

- Promacta

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Coverage excluded if intent is to solely normalize platelet counts
<b>Required Medical Information</b>	Documentation of an insufficient response or contraindications to first line therapies of immune idiopathic thrombocytopenic purpura, (e.g. corticosteroids or, immunoglobulins, or splenectomy) or if clinical condition increases the risk for bleeding. Promacta will also be covered for thrombocytopenia in pts w/chronic hep C. Diagnosis of SAA. Used for first-line treatment (e.g., patient has not received prior immunosuppressive therapy). Used in combination with standard immunosuppressive therapy. Patient meets at least two of the following: 1) Absolute neutrophil count less than 500/mcl, 2) Platelet count less than 20,000/mcl, 3) Absolute reticulocyte count less than 60,000/mcl. Refractory SAA: Diagnosis of Refractory Severe Aplastic Anemia. Patient has a platelet count less than 30,000/mcl. Insufficient response to immunosuppressive therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

# PROVIGIL

## Products Affected

- Modafinil

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Treatment of Multiple Sclerosis
<b>Required Medical Information</b>	Diagnosis of Narcolepsy confirmed by Sleep Lab evaluation. Diagnosis of Obstructive Sleep Apnea or Hypopnea Syndrome confirmed by Polysomnography and has score of 10 or more in the Epworth Sleepiness Scale. Diagnosis of Shift-Work Sleep Disorder (SWSD) confirmed by symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, or sleep study demonstrating loss of a normal sleep-wake pattern (e.g. Disturbed Chronobiologic Rhythmicity). No other medical condition or medication accounts for they symptoms.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	OSAHS (Reauth): Documentation of positive clinical response to prior therapy. SWSD (Reauth): Documentation of positive clinical response to prior therapy. Patient still requires treatment for SWSD. Narcolepsy (Reauth): Documentation of positive clinical response to prior therapy.

# PULMOZYME

---

## Products Affected

- Pulmozyme SOLN 2.5MG/2.5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. Diagnosis of Cystic Fibrosis.



# QUALAQUIN

---

## Products Affected

- Quinine Sulfate CAPS 324MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Prior authorization to ensure use for malaria

# RAVICTI

---

## Products Affected

- Ravicti

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hypersensitivity to phenylbutyrate
<b>Required Medical Information</b>	Diagnosis or Chronic Disorder of the Urea Cycle, metabolism confirmed by enzymatic, biochemical, or genetic testing
<b>Age Restrictions</b>	2 months or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Doc trial and failure, intolerance, or contraindication to Buphenyl

# REBLOZYL

---

## Products Affected

- Reblozyl

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hemoglobin (sickle) s/beta thalassemia or alpha thalassemia (e.g. hemoglobin H)
<b>Required Medical Information</b>	Diagnosis of beta-thalassemia or hemoglobin e/beta-thalassemia (may include beta-thalassemia with mutation and/or multiplication of alpha globin)
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	Initial: 3 months. Reauth: 12 months.
<b>Other Criteria</b>	N/A

# REGRANEX

---

## Products Affected

- Regranex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diabetic lower extremity ulcer
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# RELISTOR

---

## Products Affected

- Relistor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	Requires trial and failure of standard laxative therapy (docusate, senna, polyethylene glycol (Miralax), magnesium citrate, etc.). Continuation of therapy requires documentation of improvement

# REYVOW

---

## Products Affected

- Reyvow

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Reyvow will not be approved if being used in combination with Nurtec (rimegepant) or Ubrelvy (ubrogepant)
<b>Required Medical Information</b>	Initial: Diagnosis of moderate to severe migraine with or without aura according to the International Classification of Headache Disorders. For patients with 4 or more migraine days per month, there must be one of the following: Documented trial of at least one generic triptan therapy with little to no relief of moderate/severe migraine symptoms, or documented contraindication to triptan therapy defined as one of the following: I. History of stroke or transient ischemic attack II. History of hemiplegic or basilar migraine III. Peripheral vascular disease, ischemic bowel disease IV. Uncontrolled hypertension V. Recent use (within 2 weeks) of MAO Inhibitors VI. Recent use (within 24 hours) of treatment with another 5-HT1 Agonist, or an ergot-containing or ergotype medication (e.g. methysergide, dihydroergotamine) VII. Ischemic coronary artery disease (angina pectoris, history of myocardial infarction [MI], or documented silent ischemia) VIII. Coronary artery vasospasm, including Prinzmetal variant angina, or other significant underlying cardiovascular disease IX. Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders X. Patients with risk factors for CAD (e.g. hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male 40 years of age) in whom adequate cardiac evaluation has not ruled out CAD
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Neurologist, Pain Specialist, Headache Specialist or Physician who specializes in the treatment of Chronic Migraine Management
<b>Coverage Duration</b>	Initial: 12 months. Reauth: 12 months (with documentation of beneficial response).
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy (reduction in pain, photophobia, phonophobia)

# REZUROCK

---

## Products Affected

- Rezurock

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Chronic graft versus host disease (cGVHD) (initial): Diagnosis of cGVHD. Trial and failure of two or more lines of systemic therapy (e.g., corticosteroids, mycophenolate, etc.).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	cGVHD (initial): Prescribed by or in consultation with one of the following: hematologist, oncologist, or physician experienced in the management of transplant patients.
<b>Coverage Duration</b>	cGVHD (initial, reauth): 12 months
<b>Other Criteria</b>	cGVHD (reauth): Patient does not show evidence of progressive disease while on therapy.



# RIBAVIRIN ORAL INHALATION

---

## Products Affected

- Ribavirin SOLR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hypersensitivity to ribavirin or any component of the product, Pregnant women or women who may become pregnant during treatment.
<b>Required Medical Information</b>	Confirmed dx of RSV infection
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Immunologist, Infectious Disease Specialist, Pulmonologist
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Subject to BvD decision. Hospitalization due to RSV infection.

# RINVOQ

## Products Affected

- Rinvoq

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Not used in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine)
<b>Required Medical Information</b>	Atopic Dermatitis (AD)(Initial)(15 and 30mg): Diagnosis of moderate to severe atopic dermatitis, with One of the following: Involvement of at least 10% body surface area (BSA), SCORing Atopic Dermatitis (SCORAD) index value of at least 25. AND A TF/C/I minimum 30-day supply (14-day supply for topical corticosteroids) on: Medium or higher potency topical corticosteroid, Pimecrolimus cream, Tacrolimus ointment, Eucrisa (crisaborole) ointment, AND One of the following: Trial and failure of a minimum 12-week supply of at least one systemic drug product for the treatment of atopic dermatitis (examples include, but are not limited to, Adbry [tralokinumab-ldrm], Dupixent [dupilumab], etc.), OR Patient has a contraindication, intolerance, or treatment is inadvisable with both of the following FDA-approved atopic dermatitis therapies: Adbry (tralokinumab-ldrm), Dupixent (dupilumab). Psoriatic Arthritis (PsA)(Initial)(15mg): Diagnosis of active psoriatic arthritis (PsA) with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement, AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Enbrel (etanercept), Humira (adalimumab)). Rheumatoid Arthritis (RA)(Initial)(15mg): Diagnosis of moderately to severely active RA . Minimum duration of a 3-month Trial/failure, intolerance, or contraindication to one disease modifying antirheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine) at maximally indicated doses, AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Enbrel (etanercept), Humira (adalimumab)).
<b>Age Restrictions</b>	12 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an Allergist, Dermatologist, Gastroenterologist, Immunologist, Rheumatologist

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>Ulcerative Colitis (UC)(Initial): Diagnosis of moderately to severely active ulcerative colitis with One of the following: Greater than 6 stools per day, Frequent blood in the stools, Frequent urgency, Presence of ulcers, Abnormal lab values (e.g., hemoglobin, ESR, CRP), Dependent on, or refractory to, corticosteroids, AND TF/C/I to one of the following conventional therapies: 6-mercaptopurine (Purinethol), Aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)], Azathioprine (Imuran), Corticosteroids (e.g., prednisone, methylprednisolone), AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Humira (adalimumab)).</p> <p>Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline. Will not be used in combination with other JAK inhibitors, biologic DMARDS, or potent immunosuppressants (e.g., azathioprine, cyclosporine)</p>

# RUCONEST

---

## Products Affected

- Ruconest

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with laryngeal attack
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	13 years or older
<b>Prescriber Restrictions</b>	Allergist, Immunologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SAMSCA

## Products Affected

- Samsca TABS 15MG

- Tolvaptan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	To raise Serum Na urgently to prevent or to treat serious neurological symptoms
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Samsca (tolvaptan) is indicated for the tx of clinically significant hypovolemic and euvolemic hyponatremia (serum sodium 125 meq/L or less marked hyponatremia that is symptomatic), including patients with heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone (SIADH). 1-3. pt req intervention to raise serum Na urgently to prevent or to treat serious neurological symptoms should not be treated with Samsca. 1 it has not been established that raising serum sodium with Samsca provides a symptomatic benefit to patients. Should be initiated and reinitiated in patients only in a hospital where serum sodium can be monitored closely

# SIGNIFOR

---

## Products Affected

- Signifor

- Signifor Lar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Cushing's Syndrome/Disease, baseline fasting plasma glucose and/or HbA1c. Documentation that the patient had surgery that was not curative or is not a candidate for surgery.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Initials: 3 months. Reauth: 12 months.
<b>Other Criteria</b>	N/A

# SIRTURO

## Products Affected

- Sirturo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Diagnosis of latent infection due to mycobacterium, extrapulmonary or drug sensitive TB or Non-TB mycobacterial infection
<b>Required Medical Information</b>	Multi-Drug resistant TB with confirmed susceptibility data that indicate member has pulmonary MDR-TB
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Infectious Disease Specialist
<b>Coverage Duration</b>	24 weeks
<b>Other Criteria</b>	Must be used in combination with at least three other drugs to which the members MDR-TB isolate has been shown to be susceptible in vitro. MDR-TB refers to an isolate of M. TB that is resistant to at least isoniazid and rifampin and possibly additional agents. Treatment failure refers to failure of cultures to become negative during course of tx or reappearance of positive cultures after cultures convert to negative during treatment

# SKYRIZI

---

## Products Affected

- Skyrizi INJ 150MG/ML, 180MG/1.2ML, 360MG/2.4ML, 75MG/0.83ML
- Skyrizi Pen

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Psoriasis (PSO): Diagnosis of moderate to severe chronic plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement AND Minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar. Psoriatic Arthritis (PsA): Diagnosis of active psoriatic arthritis (PsA) with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement. Crohn's disease (CD) (Initial): Diagnosis of moderately to severely active CD. Will be used as a maintenance dose following the intravenous induction doses.
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Dermatologist, Rheumatologist, or Gastroenterologist
<b>Coverage Duration</b>	12 months



<b>Other Criteria</b>	Reauth: Documentation of a positive clinical response to therapy: Reduction in the body surface area (BSA) involvement from baseline or improvement in symptoms (e.g., pruritus, inflammation) from baseline, or Reduction in the total active (swollen and tender) joint count from baseline, or at least one of the following: improvement in intestinal inflammation (eg, mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline, OR reversal of high fecal output state.
-----------------------	---

# SOLIRIS

---

## Products Affected

- Soliris

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of pt having had a meningococcal vaccination at least 2 weeks prior to administration
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist, Hematologist
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Subject to BvD decision.

# SOVALDI

---

## Products Affected

- Sovaldi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Chronic Hepatitis C. Criteria will be applied consistent with current AASLD-IDSA guidance
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Coverage duration will follow recommendation set forth by the AASLD
<b>Other Criteria</b>	Genotype 1 must have trial and failure with Harvoni or Viekira Pak prior to Sovaldi

# SPRAVATO

## Products Affected

- Spravato 56mg Dose
- Spravato 84mg Dose

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	One of the following: A) Both of the following: 1) Diagnosis of major depressive disorder (treatment-resistant) and 2) Patient has not experienced a clinical meaningful improvement after treatment with at least two antidepressants from different classes for an adequate duration (at least 4 weeks each) in the current depressive episode OR B) Both of the following: 1) Diagnosis of major depressive disorder and 2) Patient has both of the following: a) depressive symptoms and b) acute suicidal ideation or behavior. Used in combination with an oral antidepressant (e.g., duloxetine, escitalopram, sertraline).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a psychiatrist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

# STELARA

## Products Affected

- Stelara INJ 45MG/0.5ML, 90MG/ML

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	<p>Crohn's Disease (CD): Diagnosis of moderately to severely active CD with One of the following: Frequent diarrhea and abdominal pain, At least 10% weight loss, Complications such as obstruction, fever, abdominal mass, Abnormal lab values (e.g., CRP), CD Activity Index (CDAI greater than 220) . Trial/failure, contraindication, or intolerance to one of the following: corticosteroid or immunosuppressant (azathioprine, 6-MP, or methotrexate) therapy. Psoriasis (PSO): Diagnosis of severe plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement, AND Minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies: Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar. Psoriatic Arthritis (PSA): Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement, AND Patient's weight is greater than 100 kg (220 lbs) for 90mg/mL strength. Ulcerative Colitis (UC): Diagnosis of moderately to severely active UC with One of the following: Greater than 6 stools per day, Frequent blood in the stools, Frequent urgency, Presence of ulcers, Abnormal lab values (e.g., hemoglobin, ESR, CRP), Dependent on, or refractory to, corticosteroids, AND Trial and failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine (Purinethol), Aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)], Azathioprine (Imuran), Corticosteroids (e.g., prednisone, methylprednisolone)</p>
<b>Age Restrictions</b>	Psoriatic Arthritis: 6 years or older. Plaque Psoriasis: 6 years or older.

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist, Gastroenterologist, Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reatuth (ALL): Documentation of positive clinical response to therapy as evidenced by improvement from baseline

# STRENSIQ

---

## Products Affected

- Strensiq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of Juvenile-Onset Hypophosphatasia or Perinatal or Infant-Onset Hypophosphatasia
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Geneticist, Endocrinologist, Metabolist Specialist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

## SUB-Q IG

---

### Products Affected

- Cuvitru
- Hizentra

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of primary immunodeficiency is the only covered indication for subcutaneous route
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. Not to be given in conditions such as ITP and neuropathies in which large doses are usually given to block FC receptor function, complement deposition or other immunomodulatory effects.



# SUCRAID

---

## Products Affected

- Sucraid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Sucrase-isomaltase deficiency, congenital
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SUNOSI

---

## Products Affected

- Sunosi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Excessive Daytime Sleepiness associated with Narcolepsy confirmed by sleep lab evaluation or Diagnosis of Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea (OSA) confirmed by sleep study. Documented trial and failure, intolerance, or contraindication to armodafinil or modafinil
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SYMDEKO

---

## Products Affected

- Symdeko

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of cystic fibrosis and homozygous for the F508del mutation or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor
<b>Age Restrictions</b>	6 years or older
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SYMLIN

---

## Products Affected

- Symlinpen 120
- Symlinpen 60

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Confirmed dx of gastroparesis. Need for meds to stimulate GI motility. HBA1c greater than 9%. Recurrent severe hypoglycemia requiring assistance in the last 6 mo. Presence of hypoglycemia unawareness. Ped patients.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Failure to achieve adequate glycemic control for adults who take mealtime insulin

# SYNAGIS

## Products Affected

- Synagis INJ 100MG/ML, 50MG/0.5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Children less than 2 years
<b>Prescriber Restrictions</b>	Pediatrician, Pediatric Pulmonologist, Cardiologist, Neurologist
<b>Coverage Duration</b>	RSV season as defined annually by the CDC.
<b>Other Criteria</b>	Infants less than 12 months born before 29 weeks gestation or those with Congenital Heart Disease, CLD or other chronic illness. 12-24 months who needed sup O2 for 28 days+ after birth and continue to need med intervention (sup O2, chronic corticosteroid or diuretic tx). Children greater than 24 months if profoundly immunocompromised during RSV season

# TADALAFIL ONCE DAILY

---

## Products Affected

- Tadalafil TABS 5MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Erectile dysfunction or concurrent use of nitrates
<b>Required Medical Information</b>	Documentation of benign prostatic hyperplasia. Patient has experienced intolerance to or treatment failure with an alpha-blocker (e.g. doxazosin, prazosin, tamsulosin) or a 5-alpha reductase inhibitor (e.g. finasteride)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TAFAMIDIS

---

## Products Affected

- Vyndamax
- Vyndaqel

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	All FDA- Approved indications: Amyloid cardiomyopathy (ATTR-CM) with TTR mutation or amyloid deposits
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TAKHZYRO

---

## Products Affected

- Takhzyro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Prophylaxis of Hereditary Angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Immunologist, Allergist, Rheumatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# TALTZ

## Products Affected

- Taltz

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS)(Initial): Diagnosis of active AS. One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Humira (adalimumab), 3) Enbrel (etanercept), 4) Xeljanz/Xeljanz XR (tofacitinib), OR B) For continuation of prior therapy if within the past 120 days. Non-Radiographic Axial Spondyloarthritis (NR-AXSPA)(Initial): Diagnosis of NR-AXSPA. Patient has objective signs of inflammation (e.g., C-reactive protein [CRP] levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints.), AND documented TF/C/I to one nonsteroidal anti-inflammatory drug (NSAID) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses, AND one of the following: A) TF/C/I to Cosentyx, OR B) For continuation of prior therapy if within the past 120 days. Psoriasis (PSO)(Initial): Diagnosis of chronic moderate to severe plaque psoriasis with One of the following: Greater than or equal to 3% body surface area involvement, Severe scalp psoriasis, Palmoplantar (i.e., palms, soles), facial, or genital involvement . One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Skyrizi (risankizumab), 5) Stelara (ustekinumab) OR B) For continuation of prior therapy if within the past 120 days.
<b>Age Restrictions</b>	PSO: 6 years or older, All others: 18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Dermatologist
<b>Coverage Duration</b>	12 months

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Other Criteria</b>	Psoriatic Arthritis (PSA)(Initial): Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement . One of the following: A) Trial/failure, contraindication, or intolerance to two of the following: 1) Cosentyx (secukinumab), 2) Enbrel (etanercept), 3) Humira (adalimumab), 4) Rinvoq (upadacitinib), 5) Skyrizi (rizankizumab), 6) Stelara (ustekinumab), 7) Xeljanz/Xeljanz XR (tofacitinib) OR B) For continuation of prior therapy within the past 120 days. Reauth: (All) Documentation of positive clinical response to therapy as evidenced by improvement from baseline
-----------------------	---

# TARGRETIN

---

## Products Affected

- Bexarotene GEL

- Targretin GEL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Cutaneous T-Cell Lymphoma (CTCL): Diagnosis of CTCL. Trial and failure, contraindication, or intolerance to at least one prior therapy (including skin-directed therapies [e.g. corticosteroids {e.g. clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate}] or systemic therapies [e.g. interferons]).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist, Dermatologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve for continuation of prior therapy

# TAZORAC

---

## Products Affected

- Tazarotene CREA
- Tazarotene GEL
- Tazorac CREA 0.05%
- Tazorac GEL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Coverage of tazarotene requires a documented condition other than cosmetic/photo aging.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TCAS

---

## Products Affected

- Clomipramine Hydrochloride
- Doxepin Hcl CAPS 75MG
- Doxepin Hcl CONC
- Doxepin Hydrochloride CAPS 100MG, 10MG, 150MG, 25MG, 50MG
- Imipramine Hcl TABS 25MG, 50MG
- Imipramine Hydrochloride TABS 10MG
- Imipramine Pamoate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Provider must submit attestation that benefit outweighs risk of drugs found to be high risk medications for beneficiaries age 65 and older
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Prior authorization is not required for anyone under the age of 65

# TERIPARATIDE

---

## Products Affected

- Forteo INJ 600MCG/2.4ML

- Teriparatide

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients who are at an increased risk of osteosarcoma, including those with Paget's Disease, unexplained elevations in serum alkaline phosphatase, prior skeletal radiation, or in children or young adults with open epiphyses
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	All uses (initial): 24 months. All uses (reauth): 12 months.
<b>Other Criteria</b>	For the tx of postmenopausal women with osteoporosis or to increase bone mass in men with primary hypogonadal osteoporosis or for the tx of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5mg or greater of prednisone) who are at high risk for fracture. High risk defined as a history of osteoporotic fracture, multiple risk factors for fracture, or pts who are intolerant to or have had failure to increase bone mass density after 6 months to 1 year tx with a bisphosphonate (in females)

# TESTOSTERONE REPLACEMENT

## Products Affected

- Danazol CAPS
- Testosterone GEL 10MG/ACT, 20.25MG/1.25GM, 25MG/2.5GM, 40.5MG/2.5GM, 50MG/5GM
- Testosterone Pump

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of male with hypogonadism with total serum testosterone less than 300ng/dL w/in 90 days or documentation of male with delayed puberty not secondary to pathological disorder or documentation of female with metastatic breast cancer
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Danazol will also be covered for the following indications: endometriosis, fibrocystic breast disease and hereditary angioedema

# TETRABENAZINE

---

## Products Affected

- Tetrabenazine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of chorea associated with Huntington Disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# TEZSPIRE

---

## Products Affected

- Tezspire

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of severe asthma, Age 12 years or older, Documented concurrent use of an inhaled corticosteroid (ICS) and one additional asthma controller medication (LABA, LAMA, or leukotriene modifier) with lack of asthma control. For patients with eosinophilic asthma, documentation of trial, failure, or contraindication to Dupixent
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with an allergist, immunologist, or pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: documentation of beneficial therapy

# THALOMID

---

## Products Affected

- Thalomid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Erythema nodosum leprosum, Erythema nodosum leprosum prophylaxis, Multiple myeloma newly diagnosed in combination with dexamethasone
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist, Infectious Disease Specialist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# TOBRAMYCIN

---

## Products Affected

- Kitabis Pak
- Tobi Podhaler
- Tobramycin NEBU 300MG/5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Cystic Fibrosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Infectious Disease Specialist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TREPROSTINIL

## Products Affected

- Orenitram
- Orenitram Titration Kit Month 1
- Orenitram Titration Kit Month 2
- Orenitram Titration Kit Month 3
- Remodulin
- Treprostinil
- Tyvaso
- Tyvaso Dpi Maintenance Kit
- Tyvaso Dpi Titration Kit
- Tyvaso Refill
- Tyvaso Starter

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Previous medications used, results of acute vasoreactivity testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. The drug is prescribed by a physician experienced in the management of pulmonary vascular disease for the treatment of pulmonary arterial hypertension in patients with NYHA Class II, III or IV symptoms.

# TRETINOIN/AZELAIC ACID

---

## Products Affected

- Avita
- Azelex
- Tretinoin CREA
- Tretinoin GEL
- Tretinoin Microsphere GEL 0.04%, 0.1%
- Tretinoin Microsphere Pump

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Cosmetic purposes (e.g., wrinkles, photoaging)
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TRIKAFTA

---

## Products Affected

- Trikafta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of Cystic fibrosis and documentation that member has at least one F508del mutation in the CFTR gene
<b>Age Restrictions</b>	For granule packets: patient is at least 2 to less than 6 years of age. For tablets: patient is 6 years of age or older.
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TYSABRI

---

## Products Affected

- Tysabri

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of moderate to severe Crohn's with inadequate response or unable to tolerate treatment with Humira (adalimumab) or documentation of relapsing forms of MS
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ULTOMIRIS

## Products Affected

- Ultomiris INJ 1100MG/11ML, 300MG/3ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Ultomiris cannot be used in combination with another terminal complement inhibitor, such as Soliris (eculizumab), Ultomiris cannot be used in patients with Shiga Toxin E. Coli related Hemolytic Uremic Syndrome (STEC-HUS)
<b>Required Medical Information</b>	Documentation of one of the following diagnoses: Paroxysmal nocturnal hemoglobinuria (PNH) and age 18 years or older, or Atypical hemolytic uremic syndrome (aHUS) and age 1 month or older
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescriber in the Ultomiris REMS Program
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: 12 months based on documentation of positive clinical response to therapy (e.g. improvement in hemolytic parameters and/or improvement in clinical symptoms)



# UPTRAVI

---

## Products Affected

- Uptravi

- Uptravi Titration Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of pulmonary arterial hypertension. Documented trial and failure, contraindication, or intolerance to sildenafil
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# VALCHLOR

---

## Products Affected

- Valchlor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma (CTCLs) in patients who have received prior skin-directed therapy
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# VASCEPA

## Products Affected

- Icosapent Ethyl
- Vascepa CAPS 0.5GM

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Severe Hypertriglyceridemia: Dx of hypertriglyceridemia and patient has a pre-treatment triglyceride (TG) level greater than or equal to 500mg/dl. Prevent of CV events: Dx of hypertriglyceridemia and patient has a pre-treatment TG level of 150 to 499mg/dl. One of the following: 1) Patient has established cardiovascular disease (CVD) (e.g. coronary artery disease, cerebrovascular or carotid disease, peripheral artery disease, etc.), or 2) Both of the following: A) Dx of diabetes mellitus and B) Patient has two or more risk factors for developing CVD. Medication will be used as an adjunct to maximally tolerated statin therapy unless there is a contraindication or intolerance to statin therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Severe Hypertriglyceridemia (Reauth): Documentation of positive clinical response to therapy. Prevention of CV events (Reauth): Documentation of positive clinical response to therapy. Medication continues to be used as an adjunct to maximally tolerated statin therapy unless there is a contraindication or intolerance to statin therapy.

# VENTAVIS

---

## Products Affected

- Ventavis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Previous medications used, results of acute vasoreactivity testing
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Pulmonologist, Cardiologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to BvD decision. For the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II, III, or IV symptoms and positive clinical response to therapy, and trial and failure of oral calcium channel blockers if acute vasoreactivity testing is positive or unless contraindicated (e.g. unstable patients or those with severe right heart failure).

# VIBERZI

## Products Affected

- Viberzi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Irritable Bowel Syndrome with Diarrhea (IBS-D): Diagnosis of IBS-D, Documented failure to respond or contraindication to loperamide, or Documented failure to respond or contraindication to at least one bile acid sequestrant (e.g. cholestyramine, colestipol, colesevelam), or Documented failure to respond or contraindication to at least one antispasmodic agent (e.g. dicyclomine, hyoscyamine).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gastroenterologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# VIMIZIM

---

## Products Affected

- Vimizim

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of mucopolysaccharidosis Type IV A (MPS IV A Morquio A Syndrome)
<b>Age Restrictions</b>	5 years or older
<b>Prescriber Restrictions</b>	Geneticist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# VORICONAZOLE INJECTION

## Products Affected

- Voriconazole INJ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Invasive aspergillosis: Diagnosis of invasive aspergillosis (IA). Candidemia: Diagnosis of candidemia. One of the following: (1) patient is non-neutropenic or (2) infection is located in skin, abdomen, kidney, bladder wall, or wounds. Esophageal Candidiasis: Diagnosis of esophageal candidiasis. Mycosis: Diagnosis of fungal infection caused by <i>Scedosporium apiospermum</i> (asexual form of <i>Pseudallescheria boydii</i> ) or <i>Fusarium</i> spp. including <i>Fusarium solani</i> . For fusariosis: Patient is intolerant of, or refractory to, other therapy (e.g., liposomal amphotericin B, amphotericin B lipid complex).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 weeks
<b>Other Criteria</b>	N/A

# VPRIV

---

## Products Affected

- Vpriv

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme Assay demonstrating deficiency of beta-glucocerebrosidase enzyme activity.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For long-term ERT for pediatric and adult patients with Type 1 Gaucher Disease



# VYEPTI

## Products Affected

- Vyepti

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Medication will not be used in combination with Botox. Medication will not be used in combination with another Calcitonin Gene-Related Peptide (CGRP) Inhibitor (injectable or oral).
<b>Required Medical Information</b>	Diagnosis of Migraine (chronic or episodic). If Chronic Migraine (CM): Documentation that medication overuse headache has been considered and potentially offending medication(s) have been discontinued. Documented trial and failure, contraindication, or intolerance to at least 2 American Headache Society level A or B migraine prophylactic therapies with claims history to support member compliance with filling at least a 90 days supply within a 120 day time frame including: Beta blockers: Level A: Metoprolol, propranolol, timolol or Level B: Atenolol, nadolol, Antidepressants: Level B: Amitriptyline, venlafaxine, Anticonvulsants: Level A: Divalproex, valproic acid, topiramate.
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Neurologist, Pain Specialist, Physician who specializes in the treatment of Migraine Management
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive response to therapy (reduction in headache frequency and/or intensity, use of acute migraine medications (e.g. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), triptans) has decreased since the start of CGRP therapy

# XELJANZ

## Products Affected

- Xeljanz

- Xeljanz Xr

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Exclusion Criteria	Not used in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or a potent immunosuppressant (e.g., azathioprine, cyclosporine)
Required Medical Information	Ankylosing Spondylitis (AS): Diagnosis of active ankylosing spondylitis with Minimum duration of a one-month Trial and failure, contraindication, or intolerance to one nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., diclofenac, ibuprofen, meloxicam, naproxen) at maximally indicated doses. Polyarticular Juvenile Idiopathic Arthritis (PJIA): Diagnosis of active PJIA with a minimum duration of a 6-week Trial/failure, contraindication, or intolerance to one of the following disease modifying anti-rheumatic drugs (DMARDs): leflunomide, methotrexate, AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Enbrel (etanercept), Humira (adalimumab)) . Psoriatic Arthritis (PSA) Diagnosis of active PSA with One of the following: Actively inflamed joints, Dactylitis, Enthesitis, Axial disease, Active skin and/or nail involvement, AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Enbrel (etanercept), Humira (adalimumab)). Rheumatoid Arthritis (RA): Diagnosis of active PSA or moderately to severely active RA. Minimum duration of a 3-month Trial/failure, intolerance, or contraindication to one disease modifying antirheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine,e). Ulcerative Colitis (UC): Diagnosis of moderately to severely active UC with One of the following: Greater than 6 stools per day, Frequent blood in the stools, Frequent urgency, Presence of ulcers, Abnormal lab values (e.g., hemoglobin, ESR, CRP), Dependent on, or refractory to, corticosteroids, AND Trial/failure, intolerance, or contraindication to a corticosteroid (e.g., prednisone, methylprednisolone), immunosuppressant, or aminosalicylates (e.g. azathioprine, 6-MP, methotrexate, mesalamine, osalazine, sulfasalazine), AND Patient has had an inadequate response or intolerance to one or more TNF inhibitors (e.g., Humira (adalimumab))

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

<b>Age Restrictions</b>	JIA: 2 years or older, All others: 18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Rheumatologist or Gastroenterologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: (All): Documentation of positive clinical response to therapy as evidenced by improvement from baseline Patient is not receiving in combination other JAK inhibitors, biologic DMARDs, or with a potent immunosuppressant (e.g., azathioprine, cyclosporine)

# XERMELO

## Products Affected

- Xermelo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Carcinoid syndrome diarrhea (Initial): Diagnosis of carcinoid syndrome diarrhea AND diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months AND used in combination with SSA therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Initial: Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
<b>Coverage Duration</b>	Initial: 6 months. Reauth: 12 months
<b>Other Criteria</b>	Carcinoid syndrome diarrhea (Reauthorization): Documentation of a positive clinical response to therapy AND drug will continue to be used in combination with SSA therapy.

# XGEVA

## Products Affected

- Xgeva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Multiple Myeloma (MM/Bone Metastasis from Solid Tumors (BMST): One of the following: 1) Diagnosis of Multiple Myeloma or 2) Diagnosis of solid tumors (e.g. breast cancer, kidney cancer, prostate cancer, thyroid cancer), and documented evidence of one or more metastatic bone lesions. Giant Cell Tumor of Bone (GCTB): Both of the following: 1) Diagnosis of Giant Cell Tumor of Bone and 2) One of the following: A) Tumor is unresectable, or B) Surgical resection is likely to result in severe morbidity. Hypercalcemia of Malignancy (HCM): Both of the following: 1) Diagnosis of Hypercalcemia of Malignancy, and 2) Trial and failure, contraindication, or intolerance to one intravenous bisphosphonate (e.g. pamidronate, Zometa (zoledronic acid)).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	MM/BMST, GCTB: 12 months. HCM: 2 months.
<b>Other Criteria</b>	Approve for continuation of prior therapy

# XIAFLEX

## Products Affected

- Xiaflex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Dupuytren's Contracture with palpable cord: Medical chart documentation stating a contracture of a MP joint or PIP joint that is greater than or equal to 30 degrees. Peyronie's Disease: Medical chart documentation stating presence of a palpable plaque and penile curvature greater than or equal to 30 degrees before start of therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Orthopedic or Hand Surgeon, Urologist
<b>Coverage Duration</b>	2 inj every 6 weeks up to 8 injections if beneficial response/penile curvature of less than 15 deg
<b>Other Criteria</b>	Treatment of adult patients with Dupuytren's Contracture with a palpable cord

# XIFAXAN

## Products Affected

- Xifaxan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Allergy to Rifamycin agents
<b>Required Medical Information</b>	200mg: Doc dx of travelers' diarrhea caused by noninvasive strains of E. Coli and doc trial and failure, contraindication, or intolerance to a fluoroquinolone or azithromycin. 500mg: Doc dx of Hepatic Encephalopathy and failure to respond to lactulose or neomycin. Or Doc dx of IBS-D without constipation defined as the presence of loose or watery stools with equal to or greater than 25% of bowel movements and hard or lumpy stools with less than 25% of bowel movements and failure to respond to loperamide.
<b>Age Restrictions</b>	Travelers Diarrhea: 12 years or older. Hepatic Encephalopathy and IBS-D without constipation: 18 years or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Travelers Diarrhea: 3 days. Hepatic Encephalopathy: 12 months. IBS-D without Constipation: 14 days.
<b>Other Criteria</b>	For IBS-D without constipation max 3 treatments per calendar year

# XOLAIR

## Products Affected

- Xolair

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Asthma: Dx severe persistent asthma, doc reactivity to at least 1 perennial aeroallergen, pretreatment Ige greater than 30IU/mL, asthma sx inadequately cont w/max tol dose of inhaled corticosteroid and LABA. CIU: Doc itchy hives for at least 6 wks and one of the following unless otherwise contraindicated: Doc fail on at least 2 diff H1 antihistamines at max tol dose or doc fail of one H1 antihist at max tol dose and inadequate response to montelukast or doc fail of one H1 antihist at max tol dose and used in comb w H2 antag at max tol dose
<b>Age Restrictions</b>	Asthma: 6 years or older. CIU: 12 years or older.
<b>Prescriber Restrictions</b>	Allergist, Pulmonologist, Dermatologist, Immunologist, Otolaryngologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Dose does not exceed FDA label max for Asthma or CIU



# XURIDEN

---

## Products Affected

- Xuriden

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Orotic Aciduria
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Geneticist, Urologist, Nephrologist, Metabolic Specialist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# XYREM

---

## Products Affected

- Sodium Oxybate
- Xyrem

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented diagnosis of narcolepsy confirmed by sleep lab evaluation or member has episodes of cataplexy including hypnagogic hallucinations and/or sleep paralysis or member has excessive daytime sleepiness with symptoms that limit the ability to perform normal daily activities
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ZAVESCA

---

## Products Affected

- Miglustat
- Yargesa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Enzyme assay demonstrating deficiency of beta-glucocerebrosidase enzyme activity
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For treatment of adult patients with mild to moderate Type 1 Gaucher Disease for whom ERT is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous access)

# ZEPATIER

## Products Affected

- Zepatier

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	All of the following: A) Criteria will be applied consistent with current AASLD/IDSA guideline and B) Patient does not have moderate to severe hepatic impairment (e.g. Child-Pugh Class B or C) and C) For Genotype 1a, patient has been tested for the presence of NS5A resistance-associated polymorphisms (e.g. polymorphisms at amino acid positions 28, 30, 31, or 93)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gastroenterologist, Infectious Disease Specialist, Hepatologist
<b>Coverage Duration</b>	Coverage duration will follow recommendation set forth by the AASLD
<b>Other Criteria</b>	N/A

# ZEPOSIA

## Products Affected

- Zeposia
- Zeposia 7-day Starter Pack
- Zeposia Starter Kit

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (initial): Diagnosis of a relapsing form of MS (e.g., clinically isolated syndrome, relapsing-remitting disease, secondary progressive disease, including active disease with new brain lesions). One of the following: a) Failure after a trial of at least 4 weeks, contraindication, or intolerance to two of the following disease-modifying therapies for MS: 1) Aubagio (teriflunomide), 2) Gilenya (fingolimod), or 3) Brand Tecfidera/generic dimethyl fumarate, OR b) for continuation of prior therapy. Ulcerative Colitis (UC) (init): Diagnosis of moderately to severely active UC. One of the following: a) Trial and failure, contraindication, or intolerance to both of the following, or attestation demonstrating a trial may be inappropriate: Humira (adalimumab), Xeljanz IR (tofacitinib IR)/Xeljanz XR (tofacitinib XR), OR b) for continuation of prior therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a Gastroenterologist , or Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Reauth: Documentation of positive clinical response to therapy as evidenced by improvement from baseline

# ZTALMY

---

## Products Affected

- Ztalmy

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Requires: 1. Diagnosis of a cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), AND Patient has a mutation in the CDKL5 gene, or 2. For continuation of prior therapy
<b>Age Restrictions</b>	2 years or older
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

## PART B VERSUS PART D

---

### Products Affected

- Acetylcysteine INHALATION SOLN
- Acyclovir Sodium INJ 50MG/ML
- Adriamycin INJ 10MG, 2MG/ML, 50MG
- Albuterol Sulfate NEBU 0.083%, 0.63MG/3ML, 1.25MG/3ML, 2.5MG/0.5ML
- Aminosyn II INJ 107.6MEQ/L; 1490MG/100ML; 1527MG/100ML; 1050MG/100ML; 1107MG/100ML; 750MG/100ML; 450MG/100ML; 990MG/100ML; 1500MG/100ML; 1575MG/100ML; 258MG/100ML; 447MG/100ML; 1083MG/100ML; 795MG/100ML; 50MEQ/L; 600MG/100ML; 300MG/100ML; 405MG/100ML; 750MG/100ML; 993MG/100ML; 1018MG/100ML; 700MG/100ML; 738MG/100ML; 500MG/100ML; 300MG/100ML; 660MG/100ML; 1000MG/100ML; 1050MG/100ML; 172MG/100ML; 270MG/100ML; 298MG/100ML; 722MG/100ML; 530MG/100ML; 400MG/100ML; 200MG/100ML; 500MG/100ML
- Aminosyn-pf INJ 46MEQ/L; 698MG/100ML; 1227MG/100ML; 527MG/100ML; 820MG/100ML; 385MG/100ML; 312MG/100ML; 760MG/100ML; 1200MG/100ML; 677MG/100ML; 180MG/100ML; 427MG/100ML; 812MG/100ML; 495MG/100ML; 70MG/100ML; 512MG/100ML; 180MG/100ML; 44MG/100ML; 673MG/100ML
- Aminosyn-pf 7% INJ 32.5MEQ/L; 490MG/100ML; 861MG/100ML; 370MG/100ML; 576MG/100ML; 270MG/100ML; 220MG/100ML; 534MG/100ML; 831MG/100ML; 475MG/100ML; 125MG/100ML; 300MG/100ML; 570MG/100ML; 347MG/100ML; 50MG/100ML; 360MG/100ML; 125MG/100ML; 44MG/100ML; 452MG/100ML
- Amphotericin B INJ
- Arformoterol Tartrate
- Asceniv
- Astagraf XL
- Azathioprine INJ
- Azathioprine TABS
- Baclofen INJ
- Bivigam INJ 10%, 5GM/50ML
- Bleomycin Sulfate INJ
- Brovana
- Budesonide SUSP
- Cladribine
- Clinimix 4.25%/dextrose 10%
- Clinimix 4.25%/dextrose 5%
- Clinimix 5%/dextrose 15%
- Clinimix 5%/dextrose 20%
- Clinimix 6/5
- Clinimix 8/10
- Clinimix 8/14
- Clinimix E 2.75%/dextrose 5% INJ 570MG/100ML; 316MG/100ML; 33MG/100ML; 5GM/100ML; 515MG/100ML; 132MG/100ML; 165MG/100ML; 201MG/100ML; 159MG/100ML; 51MG/100ML; 110MG/100ML; 454MG/100ML; 154MG/100ML; 261MG/100ML; 187MG/100ML; 138MG/100ML; 217MG/100ML; 112MG/100ML; 116MG/100ML; 50MG/100ML; 11MG/100ML; 160MG/100ML

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

- Clinimix E 4.25%/dextrose 10%
- Clinimix E 4.25%/dextrose 5%
- Clinimix E 5%/dextrose 15%
- Clinimix E 5%/dextrose 20%
- Clinimix E 8/10
- Clinimix E 8/14
- Clinisol Sf 15%
- Clinolipid
- Cromolyn Sodium NEBU
- Cyclophosphamide CAPS
- Cyclophosphamide TABS
- Cyclosporine CAPS
- Cyclosporine Modified
- Cytarabine INJ 100MG/ML, 20MG/ML
- Cytarabine Aqueous
- Dobutamine Hcl INJ 250MG/20ML
- Dobutamine Hcl/d5w INJ 5%; 1MG/ML
- Dobutamine Hydrochloride/dextrose 5%
- Dopamine Hydrochloride INJ
- Dopamine Hydrochloride/dextrose
- Dopamine/d5w INJ 5%; 3.2MG/ML
- Doxorubicin Hcl INJ 2MG/ML, 50MG
- Doxorubicin Hydrochloride INJ 10MG
- Dronabinol
- Engerix-b
- Everolimus TABS 0.25MG, 0.5MG, 0.75MG, 1MG
- Flebogamma Dif
- Floxuridine INJ
- Fluorouracil INJ 1GM/20ML, 2.5GM/50ML, 500MG/10ML, 5GM/100ML
- Freamine III INJ 89MEQ/L; 710MG/100ML; 950MG/100ML; 3MEQ/L; 24MG/100ML; 1400MG/100ML; 280MG/100ML; 690MG/100ML; 910MG/100ML; 730MG/100ML; 530MG/100ML; 560MG/100ML; 10MMOLE/L; 120MG/100ML; 1120MG/100ML; 590MG/100ML; 10MEQ/L; 400MG/100ML; 150MG/100ML; 660MG/100ML
- Gablofen
- Gammagard Liquid
- Gammagard S/d Iga Less Than 1mcg/ml
- Gammaked INJ 10GM/100ML, 1GM/10ML, 20GM/200ML, 5GM/50ML
- Gammplex INJ 10GM/100ML, 10GM/200ML, 20GM/200ML, 20GM/400ML, 5GM/100ML, 5GM/50ML
- Gamunex-c
- Ganciclovir INJ 500MG, 500MG/10ML
- Gengraf CAPS 100MG, 25MG
- Gengraf SOLN
- Granisetron Hydrochloride TABS
- Hepagam B INJ 312UNIT/ML
- Heplisav-b
- Hyperhep B
- Hyperrab
- Hyqvia
- Imogam Rabies-ht INJ 300UNIT/2ML
- Imovax Rabies (h.d.c.v.)
- Intralipid INJ 20GM/100ML, 30GM/100ML
- Ipratropium Bromide INHALATION SOLN 0.02%
- Ipratropium Bromide/albuterol Sulfate
- Kedrab
- Levalbuterol Hcl NEBU
- Levalbuterol Hydrochloride NEBU 0.63MG/3ML

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023



- Lioresal Intrathecal INJ 0.05MG/ML, 10MG/20ML, 10MG/5ML
- Milrinone Lactate In Dextrose
- Morphine Sulfate INJ 10MG/ML, 4MG/ML, 5MG/ML, 8MG/ML
- Mycophenolate Mofetil CAPS
- Mycophenolate Mofetil INJ
- Mycophenolate Mofetil SUSR
- Mycophenolate Mofetil TABS
- Mycophenolic Acid Dr
- Nabi-hb INJ 312UNIT/ML
- Nutrilipid
- Octagam
- Ondansetron Hcl SOLN
- Ondansetron Hcl TABS 24MG
- Ondansetron Hydrochloride TABS
- Ondansetron Odt
- Panzyga
- Pentamidine Isethionate INHALATION SOLR
- Plenamine INJ 147.4MEQ/L; 2.17GM/100ML; 1.47GM/100ML; 434MG/100ML; 749MG/100ML; 1.04GM/100ML; 894MG/100ML; 749MG/100ML; 1.04GM/100ML; 1.18GM/100ML; 749MG/100ML; 1.04GM/100ML; 894MG/100ML; 592MG/100ML; 749MG/100ML; 250MG/100ML; 39MG/100ML; 960MG/100ML
- Prehevbrio
- Premasol INJ 52MEQ/L; 1760MG/100ML; 880MG/100ML; 34MEQ/L; 1760MG/100ML; 372MG/100ML; 406MG/100ML; 526MG/100ML; 492MG/100ML; 492MG/100ML; 526MG/100ML; 356MG/100ML; 356MG/100ML; 390MG/100ML; 34MG/100ML; 152MG/100ML
- Privigen
- Procalamine
- Prograf PACK
- Prosol
- Rabavert
- Recombivax Hb
- Sirolimus SOLN
- Sirolimus TABS
- Tacrolimus CAPS
- Travasol INJ 52MEQ/L; 1760MG/100ML; 880MG/100ML; 34MEQ/L; 1760MG/100ML; 372MG/100ML; 406MG/100ML; 526MG/100ML; 492MG/100ML; 492MG/100ML; 526MG/100ML; 356MG/100ML; 500MG/100ML; 356MG/100ML; 390MG/100ML; 34MG/100ML; 152MG/100ML
- Trophamine INJ 0.54GM/100ML; 1.2GM/100ML; 0.32GM/100ML; 0; 0; 0.5GM/100ML; 0.36GM/100ML; 0.48GM/100ML; 0.82GM/100ML; 1.4GM/100ML; 1.2GM/100ML; 0.34GM/100ML; 0.48GM/100ML; 0.68GM/100ML; 0.38GM/100ML; 5MEQ/L; 0.025GM/100ML; 0.42GM/100ML; 0.2GM/100ML; 0.24GM/100ML; 0.78GM/100ML
- Vinblastine Sulfate INJ 1MG/ML
- Vincasar Pfs
- Vincristine Sulfate INJ
- Xembify

## Details

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

## Index Of Drugs

<b>A</b>	
Aat Deficiency.....	1
Abelcet .....	2
Abiraterone Acetate.....	122
Accutane.....	80
Acetylcysteine .....	214
Actemra .....	3
Actemra Actpen.....	3
Acyclovir Sodium .....	214
Adalimumab-adaz .....	71
Adempas.....	4
Adriamycin.....	214
Adstiladrin.....	122
Aimovig.....	5
Akeega.....	122
Albuterol Sulfate .....	214
Aldurazyme .....	6
Alecensa .....	122
Alimta.....	122
Aliqopa .....	122
Alunbrig .....	122
Alymsys.....	122
Alyq.....	138
Ambisome .....	7
Ambrisentan .....	8
Aminosyn II .....	214
Aminosyn-pf .....	214
Aminosyn-pf 7% .....	214
Amitriptyline .....	9
Amitriptyline Hcl .....	9
Amitriptyline Hydrochloride.....	9
Amjevita.....	71
Amnesteem.....	80
Amphotericin B .....	214
Amphotericin B Liposome .....	7
Antiemetic Therapies .....	10
Apokyn .....	11
Apomorphine Hydrochloride .....	11
Aponvie.....	10
Aprepitant .....	10
Aralast Np .....	1
Aranesp .....	12
Aranesp Albumin Free.....	12
Arcalyst.....	13
Arformoterol Tartrate.....	214
Armodafinil.....	118
Asceniv .....	214
Astagraf XL .....	214
Avita.....	188
Avsola .....	77
Ayvakit.....	122
Azathioprine.....	214
Azelex .....	188
<b>B</b>	
Baclofen .....	214
Balversa.....	122
Bavencio .....	122
Beleodaq .....	122
Bendamustine Hydrochloride .....	122
Bendeka.....	122
Berinert .....	14
Besponsa .....	122
Besremi .....	15
Bexarotene .....	122, 178
Bivigam.....	214
Bleomycin Sulfate.....	214
Blincyto.....	122
Bortezomib.....	122
Bosulif.....	122
Botox.....	16
Botulinum A Toxin.....	16
Braftovi .....	122
Brovana.....	214

Formulary ID: 23538, Version: 19, Effective Date: 12/01/2023

Last Updated: November 2023

Brukinsa .....	122
Budesonide .....	214
<b>C</b>	
Cablivi .....	17
Cabometyx .....	122
Calquence .....	122
Camzyos .....	18
Caprelsa .....	122
Carbaglu .....	19
Carglumic Acid .....	19
Cayston .....	20
Cerdelga .....	21
Cerezyme .....	22
Chenodal .....	23
Chlordiazepoxide/amitriptyline .....	9
Cholbam .....	24
Chorionic Gonadotropin .....	25
Chorionic Gonadotropins .....	25
Cimzia .....	26
Cimzia Starter Kit .....	26
Cinryze .....	28
Cinvanti .....	10
Cladribine .....	214
Claravis .....	80
Clinimix 4.25%/dextrose 10% .....	214
Clinimix 4.25%/dextrose 5% .....	214
Clinimix 5%/dextrose 15% .....	214
Clinimix 5%/dextrose 20% .....	214
Clinimix 6/5 .....	214
Clinimix 8/10 .....	214
Clinimix 8/14 .....	214
Clinimix E 2.75%/dextrose 5% .....	214
Clinimix E 4.25%/dextrose 10% .....	215
Clinimix E 4.25%/dextrose 5% .....	215
Clinimix E 5%/dextrose 15% .....	215
Clinimix E 5%/dextrose 20% .....	215
Clinimix E 8/10 .....	215
Clinimix E 8/14 .....	215
Clinisol Sf 15% .....	215
Clinolipid .....	215
Clomipramine Hydrochloride .....	180
Columvi .....	122

Cometriq .....	122
Copiktra .....	122
Cosela .....	29
Cosentyx .....	30
Cosentyx Sensoready Pen .....	30
Cosentyx Unoready .....	30
Cotellic .....	122
Cresemba .....	32
Crinone .....	33
Cromolyn Sodium .....	215
Crysvita .....	34
Cuvitru .....	167
Cyclobenzaprine .....	35
Cyclobenzaprine Hydrochloride .....	35
Cyclophosphamide .....	215
Cyclosporine .....	215
Cyclosporine Modified .....	215
Cyramza .....	122
Cystadrops .....	36
Cystagon .....	37
Cystaran .....	38
Cytarabine .....	215
Cytarabine Aqueous .....	215

**D**

Dactinomycin .....	122
Dalfampridine .....	39
Dalfampridine Er .....	39
Danazol .....	182
Danyelza .....	122
Darzalex .....	122
Darzalex Faspro .....	122
Daurismo .....	122
Deferasirox .....	40
Deferoxamine .....	41
Deferoxamine Mesylate .....	41
Diacomit .....	42
Dichlorphenamide .....	91
Diphenhydramine Hcl .....	69
Dobutamine Hcl .....	215
Dobutamine Hcl/d5w .....	215
Dobutamine Hydrochloride/dextrose 5% .....	215
Dopamine Hydrochloride .....	215

Dopamine Hydrochloride/dextrose .....	215
Dopamine/d5w .....	215
Doptelet .....	43
Doxepin Hcl .....	180
Doxepin Hydrochloride.....	180
Doxercalciferol.....	44
Doxorubicin Hcl.....	215
Doxorubicin Hydrochloride .....	215
Dronabinol.....	215
Dupixent .....	45
Dysport .....	16

**E**

Elahere.....	122
Elaprase .....	47
Elelyso.....	48
Eligard.....	99
Elitek .....	49
Elrexio.....	122
Elzonris.....	122
Emend.....	10
Emgality .....	50
Empaveli.....	52
Empliciti .....	122
Enbrel .....	53
Enbrel Mini .....	53
Enbrel Sureclick .....	53
Engerix-b.....	215
Enhertu .....	122
Epclusa .....	55
Epidiolex .....	56
Epkinly .....	122
Epoetin .....	57
Epogen.....	57
Epoprostenol .....	58
Epoprostenol Sodium .....	58
Erbix.....	122
Erivedge .....	122
Erleada.....	122
Erlotinib Hydrochloride .....	122
Esbriet.....	59
Everolimus .....	122, 215
Evomela.....	122

Exkivity.....	122
Exondys 51.....	60

**F**

Fabrazyme.....	61
Farydak .....	122
Fentanyl Citrate Oral Transmucosal .....	127
Fintepla .....	62
Flebogamma Dif .....	215
Floxuridine.....	215
Fluorouracil.....	215
Forteo .....	181
Fosaprepitant Dimeglumine.....	10
Fotivda .....	122
Freamine III .....	215
Fyarro.....	122

**G**

Gablofen.....	215
Galafold.....	63
Gammagard Liquid .....	215
Gammagard S/d Iga Less Than 1mcg/ml.....	215
Gammaked .....	215
Gammaplex.....	215
Gamunex-c.....	215
Ganciclovir.....	215
Gattex .....	64
Gavreto.....	122
Gazyva .....	122
Gefitinib .....	122
Gengraf .....	215
Gilotrif.....	122
Glassia.....	1
Glydo.....	136
Granisetron Hydrochloride .....	215
Growth Hormone .....	65

**H**

Hadlima.....	71
Hadlima Pushtouch.....	71
Haegarda .....	66
Harvoni .....	67
Hepagam B.....	215

Hepelisav-b .....	215
Herceptin .....	122
Herceptin Hylecta.....	122
Herzuma .....	122
Hetlioz .....	68
Hetlioz Lq.....	68
Hizentra .....	167
Hrm - Antihistamines .....	69
Hrm - Cns, Other .....	70
Humira.....	71
Humira Pediatric Crohns Disease Starter Pack...	71
Humira Pen.....	71
Humira Pen-cd/uc/hs Starter .....	71
Humira Pen-pediatric Uc Starter Pack .....	71
Humira Pen-ps/uv Starter .....	71
Hydroxyzine Hcl .....	69
Hydroxyzine Hydrochloride.....	69
Hydroxyzine Pamoate .....	69
Hyperhep B .....	215
Hyperrab.....	215
Hyqvia .....	215

## **I**

Ibrance .....	122
Icatibant.....	74
Icatibant Acetate.....	74
Iclusig.....	122
Icosapent Ethyl.....	194
Idhifa .....	122
Ilaris.....	75
Imatinib Mesylate.....	122
Imbruvica .....	122
Imfinzi .....	122
Imipramine Hcl .....	180
Imipramine Hydrochloride.....	180
Imipramine Pamoate .....	180
Imjudo .....	122
Imogam Rabies-ht .....	215
Imovax Rabies (h.d.c.v.) .....	215
Imvexxy Maintenance Pack .....	136
Imvexxy Starter Pack .....	136
Increlex.....	76
Inflectra .....	77

Infliximab.....	77
Infugem.....	122
Ingrezza.....	79
Inlyta .....	122
Inqovi .....	122
Inrebic .....	122
Intralipid.....	215
Ipratropium Bromide .....	215
Ipratropium Bromide/albuterol Sulfate.....	215
Iressa .....	122
Isotretinoin .....	80
Isturisa.....	81
Ivermectin .....	82

## **J**

Jakafi .....	83
Jaypirca .....	122
Jemperli.....	122
Juxtapid.....	84
Jynarque .....	85

## **K**

Kalbitor .....	86
Kalydeco .....	87
Kanjinti .....	122
Kanuma.....	88
Kedrab.....	215
Kepivance .....	89
Kerendia.....	90
Keveyis .....	91
Keytruda.....	122
Kimmtrak .....	122
Kineret.....	92
Kisqali.....	122
Kisqali Femara 200 Dose.....	122
Kisqali Femara 400 Dose.....	122
Kisqali Femara 600 Dose.....	123
Kitabis Pak .....	186
Korlym .....	93
Koselugo .....	123
Krazati.....	123
Krystexxa .....	94
Kuvan.....	95

**L**

Lanreotide Acetate .....	65
Lapatinib Ditosylate .....	123
Lazanda .....	96
Ledipasvir/sofosbuvir.....	67
Lemtrada.....	97
Lenalidomide.....	123
Lenvima 10 Mg Daily Dose .....	123
Lenvima 12mg Daily Dose .....	123
Lenvima 14 Mg Daily Dose .....	123
Lenvima 18 Mg Daily Dose .....	123
Lenvima 20 Mg Daily Dose .....	123
Lenvima 24 Mg Daily Dose .....	123
Lenvima 4 Mg Daily Dose .....	123
Lenvima 8 Mg Daily Dose .....	123
Leukine.....	98
Leuprolide .....	99
Leuprolide Acetate .....	99
Levalbuterol Hcl.....	215
Levalbuterol Hydrochloride .....	215
Libtayo .....	123
Lidocaine.....	100, 136
Lidocaine Hcl .....	136
Lidocaine Hcl Jelly.....	136
Lidocaine/prilocaine.....	136
Lioresal Intrathecal.....	216
Lonsurf .....	123
Lorbrena .....	123
Lumakras .....	123
Lumizyme.....	101
Lumoxiti .....	123
Lunsumio.....	123
Lupkynis.....	102
Lupron Depot (1-month) .....	99
Lupron Depot (3-month) .....	99
Lupron Depot (4-month) .....	99
Lupron Depot (6-month) .....	99
Lupron Depot-ped (1-month) .....	99
Lupron Depot-ped (3-month) .....	99
Lupron Depot-ped (6-month) .....	99
Lynparza.....	123
Lytgobi .....	123

**M**

Margenza.....	123
Marqibo.....	123
Matulane .....	123
Mavenclad.....	103
Mavyret.....	104
Megace.....	105
Megestrol Acetate .....	105
Mekinist .....	123
Mektovi .....	123
Melphalan Hydrochloride .....	123
Meprobamate .....	70
Miglustat .....	210
Milrinone Lactate In Dextrose .....	216
Modafinil.....	142
Monjuvi.....	123
Morphine Sulfate .....	216
Mozobil.....	106
Mulpleta .....	107
Mvasi.....	123
Myalept .....	108
Mycophenolate Mofetil.....	216
Mycophenolic Acid Dr .....	216
Mylotarg.....	123
Myobloc .....	16
Myorisan .....	80

**N**

Nabi-hb .....	216
Naglazyme .....	109
Natpara.....	110
Nerlynx .....	123
Nexavar .....	123
Nexletol.....	111
Nexlizet.....	112
Ninlaro .....	123
Nitisinone.....	129
Norditropin Flexpro .....	65
Novarel.....	25
Nplate .....	141
Nubeqa .....	123
Nucala .....	113

Nuedexta.....	114
Nuplazid .....	115
Nurtec .....	116
Nutrilipid.....	216
Nuvigil.....	118

**O**

Ocaliva .....	119
Octagam .....	216
Octreotide.....	120
Octreotide Acetate.....	120
Odomzo .....	123
Ofev .....	121
Ogivri .....	123
Ojjaara .....	123
Omnitrope.....	65
Oncology Agents.....	122
Ondansetron Hcl.....	216
Ondansetron Hydrochloride .....	216
Ondansetron Odt .....	216
Ontruzant.....	123
Opdivo.....	123
Opdualag .....	123
Opsumit.....	126
Oral Fentanyl Products.....	127
Orencia .....	128
Orencia Clickject.....	128
Orenitram .....	187
Orenitram Titration Kit Month 1.....	187
Orenitram Titration Kit Month 2.....	187
Orenitram Titration Kit Month 3.....	187
Orfadin .....	129
Orgovyx.....	123
Orkambi.....	130
Orladeyo .....	131
Orserdu .....	123
Osphena.....	132
Otezla .....	133
Oxandrolone .....	134
Oxervate .....	135

**P**

Padcev .....	123
--------------	-----

Panzyga.....	216
Part B Versus Part D.....	214
Part D Vs. Excluded.....	136
Pazopanib Hydrochloride.....	123
Pcsk9.....	137
Pemazyre.....	123
Pemetrexed.....	123
Pemetrexed Disodium.....	123
Pemfexy .....	123
Pentamidine Isethionate .....	216
Perjeta .....	123
Perphenazine/amitriptyline .....	9
Ph Pde5 Inhibitors.....	138
Phesgo.....	123
Piqray 200mg Daily Dose.....	123
Piqray 250mg Daily Dose.....	123
Piqray 300mg Daily Dose.....	123
Pirfenidone.....	59
Plenammine.....	216
Plerixafor.....	106
Pliaglis.....	136
Polivy .....	123
Pomalyst.....	123
Portrazza .....	123
Praluent .....	137
Pregnyl .....	25
Pregnyl W/diluent Benzyl Alcohol/nacl .....	25
Prehevbrio.....	216
Premasol.....	216
Pretomanid .....	139
Privigen.....	216
Procalamine.....	216
Procrit.....	57
Procysbi.....	140
Prograf.....	216
Prolastin-c .....	1
Promacta .....	141
Promacta And Nplate.....	141
Promethazine Hcl.....	69
Promethazine Hydrochloride .....	69
Prosol .....	216
Provigil.....	142
Pulmozyme .....	143



<b>Q</b>	
Qinlock .....	123
Qualaquin .....	144
Quinine Sulfate.....	144
<b>R</b>	
Rabavert .....	216
Ravicti .....	145
Reblozyl .....	146
Recombivax Hb.....	216
Regranex.....	147
Relistor .....	148
Remicade.....	77
Remodulin .....	187
Renflexis.....	77
Repatha.....	137
Repatha Pushtrex System.....	137
Repatha Sureclick.....	137
Retacrit .....	57
Retevmo .....	123
Revlimid.....	123
Reyvow .....	149
Rezlidhia.....	123
Rezurock.....	151
Riabni .....	123
Ribavirin.....	152
Ribavirin Oral Inhalation .....	152
Rinvoq.....	153
Rituxan .....	123
Rituxan Hycela.....	123
Rozlytrek.....	123
Rubraca.....	123
Ruconest.....	155
Ruxience.....	123
Rybrevant .....	123
Rydapt .....	123
<b>S</b>	
Sajazir.....	74
Samsca.....	156
Sandostatin Lar Depot.....	120
Sapropterin Dihydrochloride.....	95
Sarclisa .....	123
Scemblix .....	123
Serostim .....	65
Signifor .....	157
Signifor Lar.....	157
Sildenafil.....	138
Sildenafil Citrate .....	138
Sirolimus.....	216
Sirturo .....	158
Skyrizi.....	159
Skyrizi Pen.....	159
Sodium Oxybate.....	209
Sofosbuvir/velpatasvir .....	55
Soliris .....	161
Somatuline Depot.....	65
Somavert .....	65
Sorafenib.....	123
Sorafenib Tosylate .....	123
Sovaldi .....	162
Spravato .....	163
Spravato 56mg Dose.....	163
Spravato 84mg Dose.....	163
Sprycel .....	123
Stelara .....	164
Stivarga .....	123
Strensiq .....	166
Sub-q Ig.....	167
Sucraid .....	168
Sunitinib Malate.....	123
Sunosi.....	169
Sylvant .....	123
Symdeko .....	170
Symlin.....	171
Symlinpen 120 .....	171
Symlinpen 60 .....	171
Synagis.....	172
<b>T</b>	
Tabloid .....	123
Tabrecta.....	123
Tacrolimus .....	216
Tadalafil .....	138, 173
Tadalafil Once Daily.....	173
Tafamidis .....	174

Tafinlar .....	123	Truseltiq .....	124
Tagrisso .....	123	Truxima .....	124
Takhzyro.....	175	Tukysa.....	124
Taltz.....	176	Turalio.....	124
Talvey .....	123	Tysabri .....	190
Talzenna .....	123	Tyvaso.....	187
Targretin .....	178	Tyvaso Dpi Maintenance Kit .....	187
Tasigna .....	123	Tyvaso Dpi Titration Kit.....	187
Tasimelteon .....	68	Tyvaso Refill.....	187
Tazarotene .....	179	Tyvaso Starter .....	187
Tazorac .....	179		
Tazverik.....	123	<i>U</i>	
Tcas .....	180	Ukoniq.....	124
Tecentriq.....	123	Ultomiris .....	191
Tecvayli.....	123	Uptravi .....	192
Temodar .....	124	Uptravi Titration Pack.....	192
Tepmetko.....	124		
Teriparatide .....	181	<i>V</i>	
Testosterone .....	182	Valchlor.....	193
Testosterone Pump .....	182	Vanflyta.....	124
Testosterone Replacement.....	182	Vascepa.....	194
Tetrabenazine .....	183	Vectibix.....	124
Tezspire .....	184	Vegzelma .....	124
Thalomid .....	185	Velcade .....	124
Thiotepa.....	124	Venclexta .....	124
Tibsovo.....	124	Venclexta Starting Pack.....	124
Tivdak.....	124	Ventavis .....	195
Tobi Podhaler .....	186	Verzenio.....	124
Tobramycin .....	186	Viberzi.....	196
Tolvaptan.....	156	Vimizim .....	197
Toremifene Citrate .....	124	Vinblastine Sulfate.....	216
Travasol.....	216	Vincasar Pfs .....	216
Trazimera .....	124	Vincristine Sulfate .....	216
Treanda.....	124	Vitrakvi .....	124
Trelstar Mixject.....	124	Vizimpro .....	124
Treprostinil .....	187	Vonjo.....	124
Tretinoin .....	124, 188	Voriconazole .....	198
Tretinoin Microsphere.....	188	Voriconazole Injection.....	198
Tretinoin Microsphere Pump .....	188	Votrient .....	124
Tretinoin/azelaic Acid.....	188	Vpriv .....	199
Trikafta .....	189	Vyepti.....	200
Trodelvy .....	124	Vyndamax .....	174
Trophamine .....	216	Vyndaqel.....	174

Vyxeos.....	124
<b>W</b>	
Welireg.....	124
<b>X</b>	
Xalkori.....	124
Xeljanz.....	201
Xeljanz Xr.....	201
Xembify.....	216
Xeomin.....	16
Xermelo.....	203
Xgeva.....	204
Xiaflex.....	205
Xifaxan.....	206
Xolair.....	207
Xospata.....	124
Xpovio.....	124
Xpovio 60 Mg Twice Weekly.....	124
Xpovio 80 Mg Twice Weekly.....	124
Xtandi.....	124
Xuriden.....	208
Xyrem.....	209

<b>Y</b>	
Yargesa.....	210
Yervoy.....	124
Yondelis.....	124
Yonsa.....	124
<b>Z</b>	
Zavesca.....	210
Zejula.....	124
Zelboraf.....	124
Zemaira.....	1
Zenatane.....	80
Zepatier.....	211
Zeposia.....	212
Zeposia 7-day Starter Pack.....	212
Zeposia Starter Kit.....	212
Zepzelca.....	124
Zoladex.....	124
Zolinza.....	124
Ztalmy.....	213
Zydelig.....	124
Zykadia.....	124
Zynlonta.....	124
Zynyz.....	124